Dual GLP-1/glucagon receptor agonists

Information

  • Patent Grant
  • 9694053
  • Patent Number
    9,694,053
  • Date Filed
    Friday, December 12, 2014
    9 years ago
  • Date Issued
    Tuesday, July 4, 2017
    7 years ago
Abstract
The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
Description
FIELD OF THE INVENTION

The present invention relates to exendin-4 peptide derivatives which—in contrast to the pure GLP-1 agonist exendin-4—activate both the GLP-1 and the Glucagon receptor and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.


BACKGROUND OF THE INVENTION

Exendin-4 is a 39 amino acid peptide which is produced by the salivary glands of the Gila monster (Heloderma suspectum) (Eng, J. et al., J. Biol. Chem., 267:7402-05, 1992). Exendin-4 is an activator of the glucagon-like peptide-1 (GLP-1) receptor, whereas it does not activate significantly the glucagon receptor.


Exendin-4 shares many of the glucoregulatory actions observed with GLP-1. Clinical and nonclinical studies have shown that exendin-4 has several beneficial antidiabetic properties including a glucose dependent enhancement in insulin synthesis and secretion, glucose dependent suppression of glucagon secretion, slowing down gastric emptying, reduction of food intake and body weight, and an increase in beta-cell mass and markers of beta cell function (Gentilella R et al., Diabetes Obes Metab., 11:544-56, 2009; Norris S L et al, Diabet Med., 26:837-46, 2009; Bunck M C et al, Diabetes Care., 34:2041-7, 2011).


These effects are beneficial not only for diabetics but also for patients suffering from obesity. Patients with obesity have a higher risk of getting diabetes, hypertension, hyperlipidemia, cardiovascular and musculoskeletal diseases.


Relative to GLP-1, exendin-4 is resistant to cleavage by dipeptidyl peptidase-4 (DPP4) resulting in a longer half-life and duration of action in vivo (Eng J., Diabetes, 45 (Suppl 2):152A (abstract 554), 1996).


Exendin-4 was also shown to be much more stable towards degradation by neutral endopeptidase (NEP), when compared to GLP-1, glucagon or oxyntomodulin (Endocrinology, 150(4), 1712-1721, 2009). Nevertheless, exendin-4 is chemically labile due to methionine oxdiation in position 14 (Hargrove D M et al., Regul. Pept., 141: 113-9, 2007) as well as deamidation and isomerization of asparagine in position 28 (WO 2004/035623).


The amino acid sequence of exendin-4 is shown as SEQ ID NO: 1











HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2






The amino acid sequence of GLP-1(7-36)-amide is shown as SEQ ID NO 2











HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2






Liraglutide is a marketed chemically modified GLP-1 analog in which, among other modifications, a fatty acid is linked to a lysine in position 20 leading to a prolonged duration of action (Drucker D J et al, Nature Drug Disc. Rev. 9, 267-268, 2010; Buse, J. B. et al., Lancet, 374:39-47, 2009).


The amino acid sequence of Liraglutide is shown as SEQ ID NO 4.











HAEGTFTSDVSSYLEGQAAK((S)-4-Carboxy-4-hexa-







decanoylamino-butyryl-)EFIAWLVRGRG-OH






Glucagon is a 29-amino acid peptide which is released into the bloodstream when circulating glucose is low. Glucagon's amino acid sequence is shown in SEQ ID NO 3.











HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH






During hypoglycemia, when blood glucose levels drop below normal, glucagon signals the liver to break down glycogen and release glucose, causing an increase of blood glucose levels to reach a normal level. Hypoglycemia is a common side effect of insulin treated patients with hyperglycemia (elevated blood glucose levels) due to diabetes. Thus, glucagon's most predominant role in glucose regulation is to counteract insulin action and maintain blood glucose levels.


Hoist (Hoist, J. J. Physiol. Rev. 2007, 87, 1409) and Meier (Meier, J. J. Nat. Rev. Endocrinol. 2012, 8, 728) describe that GLP-1 receptor agonists, such as GLP-1, liraglutide and exendin-4, have 3 major pharmacological activities to improve glycemic control in patients with T2DM by reducing fasting and postprandial glucose (FPG and PPG): (i) increased glucose-dependent insulin secretion (improved first- and second-phase), (ii) glucagon suppressing activity under hyperglycemic conditions, (iii) delay of gastric emptying rate resulting in retarded absorption of meal-derived glucose.


Pocai et al (Obesity. 2012; 20:1566-1571; Diabetes 2009, 58, 2258) and Day et al. (Nat Chem Biol 2009; 5:749) describe that dual activation of the GLP-1 and glucagon receptors, e.g., by combining the actions of GLP-1 and glucagon in one molecule leads to a therapeutic principle with anti-diabetic action and a pronounced weight lowering effect


Peptides which bind and activate both the glucagon and the GLP-1 receptor (Hjort et al. Journal of Biological Chemistry, 269, 30121-30124, 1994; Day J W et al, Nature Chem Biol, 5: 749-757, 2009) and suppress body weight gain and reduce food intake are described in patent applications WO 2008/071972, WO 2008/101017, WO 2009/155258, WO 2010/096052, WO 2010/096142, WO 2011/075393, WO 2008/152403, WO 2010/070251, WO 2010/070252, WO 2010/070253, WO 2010/070255, WO 2011/160630, WO 2011/006497, WO 2011/152181, WO 2011/152182, WO2011/117415, WO2011/117416, and WO 2006/134340, the contents of which are herein incorporated by reference.


In addition, triple co-agonist peptides which not only activate the GLP-1 and the glucagon receptor, but also the GIP receptor are described in WO 2012/088116 and by VA Gault et al (Biochem Pharmacol, 85, 16655-16662, 2013; Diabetologia, 56, 1417-1424, 2013).


Bloom et al. (WO 2006/134340) disclose that peptides which bind and activate both the glucagon and the GLP-1 receptor can be constructed as hybrid molecules from glucagon and exendin-4, where the N-terminal part (e.g. residues 1-14 or 1-24) originate from glucagon and the C-terminal part (e.g. residues 15-39 or 25-39) originate from exendin-4.


D E Otzen et al (Biochemistry, 45, 14503-14512, 2006) disclose that N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon, due to the hydrophobicity and/or high β-sheet propensity of the underlying residues.


Compounds of this invention are exendin-4 peptide analogues comprising leucine in position 10 as well as position 13.


Krstenansky et al (Biochemistry, 25, 3833-3839, 1986) show the importance of the residues 10-13 of glucagon (YSKY) for its receptor interactions and activation of adenylate cyclase. In the exendin-4 derivatives described in this invention, several of the underlying residues are different from glucagon. In particular residues Tyr10 and Tyr13, which are known to contribute to the fibrillation of glucagon (D E Otzen, Biochemistry, 45, 14503-14512, 2006) are replaced by Leu, a non-aromatic amino acid, in position 10 as well as position 13. This replacement, especially in combination with isoleucine in position 23 and glutamate in position 24, leads to exendin-4 derivatives with potentially improved biophysical properties as solubility or aggregation behaviour in solution. In addition, this replacement together with Leu in position 14 leads to the formation of a so called LXXLL motif. It is known from the literature that such LXXLL motifs have a high predisposition to form a α-helical structure upon binding (Ji-Hye Yun et al., Bull. Korean Chem. Soc. 2012, Vol. 33, No. 2 583, A: K. Shiau et al. Cell, 1998, 95, 927-937.) Surprisingly it was found that the compounds of this invention show a high activity on the glucagon receptor.


Compounds of this invention are more resistant to cleavage by neutral endopeptidase (NEP) and dipeptidyl peptidase-4 (DPP4), resulting in a longer half-life and duration of action in vivo, when compared with GLP-1 and glucagon. Compounds of this invention preferably are soluble not only at neutral pH, but also at pH 4.5. This property potentially allows co-formulation for a combination therapy with an insulin or insulin derivative and preferably with a basal insulin like insulin glargine/Lantus®.


BRIEF SUMMARY OF THE INVENTION

Provided herein are exendin-4 derivatives which potently activate the GLP1 and the glucagon receptor and optionally the GIP receptor. In these exendin-4 derivatives—among other substitutions—methionine at position 14 is replaced by leucin


The invention provides a peptidic compound having the formula (I):

R1—Z—R2  (I)

wherein Z is a peptide moiety having the formula (II)

His-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Leu-Leu-Asp-Glu-Gln-X18-Ala-Lys-Asp-Phe-Ile-Glu-Trp-Leu-Ile-Ala-Gly-Gly-Pro-X32-Ser-Gly-Ala-Pro-Pro-Pro-Ser   (II)

    • X2 represents an amino acid residue selected from Ser, D-Ser and Aib,
    • X3 represents an amino acid residue selected from Gln and His,
    • X18 represents an amino acid residue selected from Arg and Leu,
    • X32 represents an amino acid residue selected from Ser and Val,
    • R1 represents NH2,
    • R2 represents OH or NH2,
    • or a salt or solvate thereof.


The compounds of the invention are GLP-1 and glucagon receptor agonists and optionally GIP receptor agonists as determined by the observation that they are capable of stimulating intracellular cAMP formation.


According to another embodiment the peptidic compounds of the invention exhibit a relative activity of at least 0.1% (i.e. EC50<700 pM), preferably at least 0.7% (i.e. EC50<100 pM), more preferably at least 1.4% (i.e. EC50<50 pM) and even more preferably at least 7% (i.e. EC50<10 pM) compared to that of GLP-1(7-36) at the GLP-1 receptor (EC50=0.7 pM).


According to another embodiment the peptidic compounds of the invention exhibit a relative activity of at least 0.1% (i.e. EC50<1000 pM), preferably at least 0.33% (i.e. EC50<300 pM), more preferably at least 1% (i.e. EC50<100 pM) and even more preferably at least 1.66% (i.e. EC50<60 pM) compared to that of natural glucagon at the glucagon receptor (EC50=1.0 pM).


The term “activity” as used herein preferably refers to the capability of a compound to activate the human GLP-1 receptor and the human glucagon receptor. More preferably the term “activity” as used herein refers to the capability of a compound to stimulate intracellular cAMP formation. The term “relative activity” as used herein is understood to refer to the capability of a compound to activate a receptor in a certain ratio as compared to another receptor agonist or as compared to another receptor. The activation of the receptors by the agonists (e.g. by measuring the cAMP level) is determined as described herein, e.g. as described in the examples.


The compounds of the invention preferably have an EC50 for hGLP-1 receptor of 100 pmol or less, more preferably of 90 pmol or less, more preferably of 80 pmol or less, more preferably of 70 pmol or less, more preferably of 60 pmol or less, more preferably of 50 pmol or less, more preferably of 40 pmol or less, more preferably of 30 pmol or less, more preferably of 25 pmol or less, more preferably of 20 pmol or less, more preferably of 15 pmol or less, more preferably of 10 pmol or less, more preferably of 9 pmol or less, more preferably of 8 pmol or less, more preferably of 7 pmol or less, more preferably of 6 pmol or less, and more preferably of 5 pmol or less more preferably of 4 pmol or less, more preferably of 3 pmol or less, and more preferably of 2 pmol or less and/or an EC50 for hGlucagon receptor of 300 pmol or less, preferably of 200 pmol or less; more preferably of 150 pmol or less, more preferably of 100 pmol or less, more preferably of 90 pmol or less, more preferably of 80 pmol or less, more preferably of 70 pmol or less, more preferably of 60 pmol or less, more preferably of 50 pmol or less, more preferably of 40 pmol or less, more preferably of 30 pmol or less, more preferably of 25 pmol or less, more preferably of 20 pmol or less, more preferably of 15 pmol or less, more preferably of 10 pmol or less. It is particularly preferred that the EC50 for both receptors is 100 pmol or less, more preferably of 90 pmol or less, more preferably of 80 pmol or less, more preferably of 70 pmol or less, more preferably of 60 pmol or less, more preferably of 50 pmol or less, more preferably of 40 pmol or less, more preferably of 30 pmol or less, more preferably of 25 pmol or less, more preferably of 20 pmol or less, more preferably of 15 pmol or less, more preferably of 10 pmol or less. The EC50 for hGLP-1 receptor and hGlucagon receptor may be determined as described in the Methods herein and as used to generate the results described in Example 4.


According to another embodiment, the compounds of the invention have an EC50 for hGIP receptor of 500 pM or less, more preferably 200 pM or less, more preferably 150 pM or less, more preferably 100 pM or less, more preferably 90 pM or less, more preferably 80 pM or less, more preferably 70 pM or less, more preferably 60 pM or less, more preferably 50 pM or less, more preferably 40 pM or less, more preferably 30 pM or less, more preferably 20 pM or less, more preferably of 10 pmol or less.


In still another embodiment, the EC50 for all three receptors, i.e. for the hGLP-1 receptor, for the hGlucagon receptor and for the hGIP receptor, is 500 pM or less, more preferably 200 pM or less, more preferably 150 pM or less, more preferably 100 pM or less, more preferably 90 pM or less, more preferably 80 pM or less, more preferably 70 pM or less, more preferably 60 pM or less, more preferably 50 pM or less, more preferably 40 pM or less, more preferably 30 pM or less, more preferably 20 pM or less, more preferably of 10 pmol or less.


The compounds of the invention have the ability to reduce the intestinal passage, increase the gastric content and/or to reduce the food intake of a patient. These activities of the compounds of the invention can be assessed in animal models known to the skilled person. Preferred compounds of the invention may increase the gastric content of mice, preferably of female NMRI-mice, if administered as a single subcutaneous dose, at least by 25%, more preferably by at least 30%, more preferably by at least 40%, more preferably by at least 50%, more preferably by at least 60%, more preferably by at least 70%, more preferably by at least 80%. Preferably, this result is measured 1 h after administration of the respective compound and 30 mins after administration of a bolus, and/or reduces intestinal passage of mice, preferably of female NMRI-mice, if administered as a single subcutaneous dose, at least by 45%; more preferably by at least 50%, more preferably by at least 55%, more preferably by at least 60%, and more preferably at least 65%; and/or reduces food intake of mice, preferably of female NMRI-mice, if administered as a single subcutaneous dose by at least 10%, more preferably 15%, and more preferably 20%.


The compounds of the invention have the ability to reduce blood glucose level, and/or to reduce HbA1c levels of a patient. These activities of the compounds of the invention can be assessed in animal models known to the skilled person and also described herein in the Methods. Preferred compounds of the invention may reduce blood glucose levels of mice, preferably in female leptin-receptor deficient diabetic db/db mice, if administered as a single subcutaneous dose of 0.1 mg/kg body weight by at least 4 mmol/L; more preferably by at least 8 mmol/L, more preferably by at least 12 mmol/L.


The compounds of the invention have the ability to reduce body weight of a patient. These activities of the compounds of the invention can be assessed in animal models known to the skilled person.


Surprisingly, it was found that peptidic compounds of the formula (I) showed very potent GLP-1 and Glucagon receptor activation


Furthermore, oxidation (in vitro or in vivo) of methionine, present in the core structure of exendin-4, is not possible anymore for peptidic compounds of the formula (I).


In one embodiment the compounds of the invention have a high solubility at acidic and/or physiological pH values, e.g., at pH 4.5 and/or at pH 7.4 at 25° C., in another embodiment at least 0.5 mg/ml and in a particular embodiment at least 1.0 mg/ml.


Furthermore, the compounds of the invention preferably have a high stability when stored in solution. Preferred assay conditions for determining the stability is storage for 7 days at 40° C. in solution at pH 4.5 or pH 7. The remaining amount of peptide is determined by chromatographic analyses as described in the Examples. Preferably, after 7 days at 40° C. in solution at pH 4.5 or pH 7 the remaining peptide amount is at least 80%, more preferably at least 85%, even more preferably at least 90% and even more preferably at least 95%.


Preferably, the compounds of the present invention comprise a peptide moiety Z (II) which is a linear sequence of 39 amino carboxylic acids, particularly α-amino carboxylic acids linked by peptide, i.e. carboxamide bonds.


A further embodiment relates to a group of compounds, wherein

    • R2 is NH2.


A further embodiment relates to a group of compounds, wherein

    • X2 represents D-Ser,
    • X3 represents an amino acid residue selected from Gln and His,
    • X18 represents an amino acid residue selected from Arg and Leu,
    • X32 represents an amino acid residue selected from Ser and Val.


A further embodiment relates to a group of compounds, wherein

    • X2 represents an amino acid residue selected from Ser, D-Ser and Aib,
    • X3 represents His,
    • X18 represents an amino acid residue selected from Arg and Leu, particularly Leu,
    • X32 represents an amino acid residue selected from Ser and Val.


A further embodiment relates to a group of compounds, wherein

    • X2 represents D-Ser,
    • X3 represents Gln,
    • X18 represents Arg,
    • X32 represents an amino acid residue selected from Ser and Val.


A further embodiment relates to a group of compounds, wherein

    • X2 represents an amino acid residue selected from Ser, D-Ser and Aib,
    • X3 represents an amino acid residue selected from Gln and His,
    • X18 represents an amino acid residue selected from Arg and Leu,
    • X32 represents Ser.


Specific examples of peptidic compounds of formula (I) are the compounds of SEQ ID NO: 5-9, as well as salts and solvates thereof.


In certain embodiments, i.e. when the compound of formula (I) comprises genetically encoded amino acid residues, the invention further provides a nucleic acid (which may be DNA or RNA) encoding said compound, an expression vector comprising such a nucleic acid, and a host cell containing such a nucleic acid or expression vector.


In a further aspect, the present invention provides a composition comprising a compound of the invention in admixture with a carrier. In preferred embodiments, the composition is a pharmaceutically acceptable composition and the carrier is a pharmaceutically acceptable carrier. The compound of the invention may be in the form of a salt, e.g. a pharmaceutically acceptable salt or a solvate, e.g. a hydrate. In still a further aspect, the present invention provides a composition for use in a method of medical treatment, particularly in human medicine.


In certain embodiments, the nucleic acid or the expression vector may be used as therapeutic agents, e.g. in gene therapy.


The compounds of formula (I) are suitable for therapeutic application without an additionally therapeutically effective agent. In other embodiments, however, the compounds are used together with at least one additional therapeutically active agent, as described in “combination therapy”.


The compounds of formula (I) are particularly suitable for the treatment or prevention of diseases or disorders caused by, associated with and/or accompanied by disturbances in carbohydrate and/or lipid metabolism, e.g. for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity and metabolic syndrome. Further, the compounds of the invention are particularly suitable for the treatment or prevention of degenerative diseases, particularly neurodegenerative diseases.


The compounds described find use, inter alia, in preventing weight gain or promoting weight loss. By “preventing” is meant inhibiting or reducing when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of a disorder.


The compounds of the invention may cause a decrease in food intake and/or increase in energy expenditure, resulting in the observed effect on body weight.


Independently of their effect on body weight, the compounds of the invention may have a beneficial effect on circulating cholesterol levels, being capable of improving lipid levels, particularly LDL, as well as HDL levels (e.g. increasing HDL/LDL ratio).


Thus, the compounds of the invention can be used for direct or indirect therapy of any condition caused or characterised by excess body weight, such as the treatment and/or prevention of obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea. They may also be used for treatment and prevention of the metabolic syndrome, diabetes, hypertension, atherogenic dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, or stroke. Their effects in these conditions may be as a result of or associated with their effect on body weight, or may be independent thereof.


Preferred medical uses include delaying or preventing disease progression in type 2 diabetes, treating metabolic syndrome, treating obesity or preventing overweight, for decreasing food intake, increase energy expenditure, reducing body weight, delaying the progression from impaired glucose tolerance (IGT) to type 2 diabetes; delaying the progression from type 2 diabetes to insulin-requiring diabetes; regulating appetite; inducing satiety; preventing weight regain after successful weight loss; treating a disease or state related to overweight or obesity; treating bulimia; treating binge eating; treating atherosclerosis, hypertension, type 2 diabetes, IGT, dyslipidemia, coronary heart disease, hepatic steatosis, treatment of beta-blocker poisoning, use for inhibition of the motility of the gastrointestinal tract, useful in connection with investigations of the gastrointestinal tract using techniques such as X-ray, CT- and NMR-scanning.


Further preferred medical uses include treatment or prevention of degenerative disorders, particularly neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ataxia, e.g. spinocerebellar ataxia, Kennedy disease, myotonic dystrophy, Lewy body dementia, multi-systemic atrophy, amyotrophic lateral sclerosis, primary lateral sclerosis, spinal muscular atrophy, prion-associated diseases, e.g. Creutzfeldt-Jacob disease, multiple sclerosis, telangiectasia, Batten disease, corticobasal degeneration, corticobasal degeneration, subacute combined degeneration of spinal cord, Tabes dorsalis, Tay-Sachs disease, toxic encephalopathy, infantile Refsum disease, Refsum disease, neuroacanthocytosis, Niemann-Pick disease, Lyme disease, Machado-Joseph disease, Sandhoff disease, Shy-Drager syndrome, wobbly hedgehog syndrome, proteopathy, cerebral β-amyloid angiopathy, retinal ganglion cell degeneration in glaucoma, synucleinopathies, tauopathies, frontotemporal lobar degeneration (FTLD), dementia, cadasil syndrome, hereditary cerebral hemorrhage with amyloidosis, Alexander disease, seipinopathies, familial amyloidotic neuropathy, senile systemic amyloidosis, serpinopathies, AL (light chain) amyloidosis (primary systemic amyloidosis), AH (heavy chain) amyloidosis, AA (secondary) amyloidosis, aortic medial amyloidosis, ApoAI amyloidosis, ApoAII amyloidosis, ApoAIV amyloidosis, familial amyloidosis of the Finnish type (FAF), Lysozyme amyloidosis, Fibrinogen amyloidosis, Dialysis amyloidosis, Inclusion body myositis/myopathy, Cataracts, Retinitis pigmentosa with rhodopsin mutations, medullary thyroid carcinoma, cardiac atrial amyloidosis, pituitary prolactinoma, Hereditary lattice corneal dystrophy, Cutaneous lichen amyloidosis, Mallory bodies, corneal lactoferrin amyloidosis, pulmonary alveolar proteinosis, odontogenic (Pindborg) tumor amyloid, cystic fibrosis, sickle cell disease or critical illness myopathy (CIM).


Further medical uses include treatment of hyperglycemia, type 2 diabetes, obesity, particularly type 2 diabetes.







DETAILED DESCRIPTION OF THE INVENTION

Definitions


The amino acid sequences of the present invention contain the conventional one letter and three letter codes for naturally occurring amino acids, as well as generally accepted three letter codes for other amino acids, such as Aib (α-aminoisobutyric acid).


Furthermore, the following code was used for the amino acid shown in Table 1:











TABLE 1





Name
Structure
code







(S)-α-methyl-lysine


embedded image


(S)MeLys









The term “native exendin-4” refers to native exendin-4 having the sequence











(SEQ ID NO: 1)



HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2.






The invention provides peptidic compounds as defined above.


The peptidic compounds of the present invention comprise a linear backbone of amino carboxylic acids linked by peptide, i.e. carboxamide bonds. Preferably, the amino carboxylic acids are α-amino carboxylic acids and more preferably L-α-amino carboxylic acids, unless indicated otherwise. The peptidic compounds preferably comprise a backbone sequence of 39 amino carboxylic acids.


For the avoidance of doubt, in the definitions provided herein, it is generally intended that the sequence of the peptidic moiety (II) differs from native exendin-4 at least at one of those positions which are stated to allow variation. Amino acids within the peptide moiety (II) can be considered to be numbered consecutively from 1 to 39 in the conventional N-terminal to C-terminal direction. Reference to a “position” within peptidic moiety (II) should be constructed accordingly, as should reference to positions within native exendin-4 and other molecules.


In a further aspect, the present invention provides a composition comprising a compound of the invention as described herein, or a salt or solvate thereof, in admixture with a carrier.


The invention also provides the use of a compound of the present invention for use as a medicament, particularly for the treatment of a condition as described below.


The invention also provides a composition wherein the composition is a pharmaceutically acceptable composition, and the carrier is a pharmaceutically acceptable carrier.


Peptide Synthesis


The skilled person is aware of a variety of different methods to prepare peptides that are described in this invention. These methods include but are not limited to synthetic approaches and recombinant gene expression. Thus, one way of preparing these peptides is the synthesis in solution or on a solid support and subsequent isolation and purification. A different way of preparing the peptides is gene expression in a host cell in which a DNA sequence encoding the peptide has been introduced. Alternatively, the gene expression can be achieved without utilizing a cell system. The methods described above may also be combined in any way.


A preferred way to prepare the peptides of the present invention is solid phase synthesis on a suitable resin. Solid phase peptide synthesis is a well-established methodology (see for example: Stewart and Young, Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, Ill., 1984; E. Atherton and R. C. Sheppard, Solid Phase Peptide Synthesis. A Practical Approach, Oxford-IRL Press, New York, 1989). Solid phase synthesis is initiated by attaching an N-terminally protected amino acid with its carboxy terminus to an inert solid support carrying a cleavable linker. This solid support can be any polymer that allows coupling of the initial amino acid, e.g. a trityl resin, a chlorotrityl resin, a Wang resin or a Rink resin in which the linkage of the carboxy group (or carboxamide for Rink resin) to the resin is sensitive to acid (when Fmoc strategy is used). The polymer support must be stable under the conditions used to deprotect the α-amino group during the peptide synthesis.


After the first amino acid has been coupled to the solid support, the α-amino protecting group of this amino acid is removed. The remaining protected amino acids are then coupled one after the other in the order represented by the peptide sequence using appropriate amide coupling reagents, for example BOP (benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium), HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium), HATU (O-(7-azabenztriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium) or DIC (N,N′-diisopropylcarbodiimide)/HOBt (1-hydroxybenzotriazol), wherein BOP, HBTU and HATU are used with tertiary amine bases. Alternatively, the liberated N-terminus can be functionalized with groups other than amino acids, for example carboxylic acids, etc.


Usually, reactive side-chain groups of the amino acids are protected with suitable blocking groups. These protecting groups are removed after the desired peptides have been assembled. They are removed concomitantly with the cleavage of the desired product from the resin under the same conditions. Protecting groups and the procedures to introduce protecting groups can be found in Protective Groups in Organic Synthesis, 3d ed., Greene, T. W. and Wuts, P. G. M., Wiley & Sons (New York: 1999).


In some cases it might be desirable to have side-chain protecting groups that can selectively be removed while other side-chain protecting groups remain intact. In this case the liberated functionality can be selectively functionalized. For example, a lysine may be protected with an ivDde protecting group (S. R. Chhabra et al., Tetrahedron Lett. 39, (1998), 1603) which is labile to a very nucleophilic base, for example 4% hydrazine in DMF (dimethyl formamide). Thus, if the N-terminal amino group and all side-chain functionalities are protected with acid labile protecting groups, the ivDde ([1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl) group can be selectively removed using 4% hydrazine in DMF and the corresponding free amino group can then be further modified, e.g. by acylation. The lysine can alternatively be coupled to a protected amino acid and the amino group of this amino acid can then be deprotected resulting in another free amino group which can be acylated or attached to further amino acids.


Finally the peptide is cleaved from the resin. This can be achieved by using King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266). The raw material can then be purified by chromatography, e.g. preparative RP-HPLC, if necessary.


Potency


As used herein, the term “potency” or “in vitro potency” is a measure for the ability of a compound to activate the receptors for GLP-1, glucagon or optionally GIP in a cell-based assay. Numerically, it is expressed as the “EC50 value”, which is the effective concentration of a compound that induces a half maximal increase of response (e.g. formation of intracellular cAMP) in a dose-response experiment.


Therapeutic Uses


According to one aspect, the compounds of the invention are for use in medicine, particularly human medicine.


The compounds of the invention are agonists for the receptors for GLP-1 and for glucagon as well as optionally for GIP (e.g. “dual or trigonal agonists”) and may provide an attractive option for targeting the metabolic syndrome by allowing simultaneous treatment of obesity and diabetes.


Metabolic syndrome is a combination of medical disorders that, when occurring together, increase the risk of developing type 2 diabetes, as well as atherosclerotic vascular disease, e.g. heart disease and stroke. Defining medical parameters for the metabolic syndrome include diabetes mellitus, impaired glucose tolerance, raised fasting glucose, insulin resistance, urinary albumin secretion, central obesity, hypertension, elevated triglycerides, elevated LDL cholesterol and reduced HDL cholesterol.


Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health and life expectancy and due to its increasing prevalence in adults and children it has become one of the leading preventable causes of death in modern world. It increases the likelihood of various other diseases, including heart disease, type 2 diabetes, obstructive sleep apnea, certain types of cancer, as well as osteoarthritis, and it is most commonly caused by a combination of excess food intake, reduced energy expenditure, as well as genetic susceptibility.


Diabetes mellitus, often simply called diabetes, is a group of metabolic diseases in which a person has high blood sugar levels, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced. The most common types of diabetes are: (1) type 1 diabetes, where the body fails to produce insulin; (2) type 2 diabetes, where the body fails to use insulin properly, combined with an increase in insulin deficiency over time, and (3) gestational diabetes, where women develop diabetes due to their pregnancy. All forms of diabetes increase the risk of long-term complications, which typically develop after many years. Most of these long-term complications are based on damage to blood vessels and can be divided into the two categories “macrovascular” disease, arising from atherosclerosis of larger blood vessels and “microvascular” disease, arising from damage of small blood vessels. Examples for macrovascular disease conditions are ischemic heart disease, myocardial infarction, stroke and peripheral vascular disease. Examples for microvascular diseases are diabetic retinopathy, diabetic nephropathy, as well as diabetic neuropathy.


The receptors for GLP-1, glucagon and GIP are members of the family B of G-protein coupled receptors. They are highly related to each other and share not only a significant level of sequence identity, but have also similar mechanisms of ligand recognition and intracellular signaling pathways.


Similarly, the peptides GLP-1, GIP and glucagon share regions of high sequence identity/similarity. GLP-1 and glucagon are produced from a common precursor, preproglucagon, which is differentially processed in a tissue-specific manner to yield e.g. GLP-1 in intestinal endocrine cells and glucagon in alpha cells of pancreatic islets. GIP is derived from a larger proGIP prohormone precurser and is synthesized and released from K-cells located in the small intestine.


The peptidic incretin hormones GLP-1 and GIP are secreted by intestinal endocrine cells in response to food and account for up to 70% of meal-stimulated insulin secretion. Evidence suggests that GLP-1 secretion is reduced in subjects with impaired glucose tolerance or type 2 diabetes, whereas responsiveness to GLP-1 is still preserved in these patients. Thus, targeting of the GLP-1 receptor with suitable agonists offers an attractive approach for treatment of metabolic disorders, including diabetes. The receptor for GLP-1 is distributed widely, being found mainly in pancreatic islets, brain, heart, kidney and the gastrointestinal tract. In the pancreas, GLP-1 acts in a strictly glucose-dependent manner by increasing secretion of insulin from beta cells. This glucose-dependency shows that activation of GLP-1 receptors is unlikely to cause hypoglycemia. Also the receptor for GIP is broadly expressed in peripheral tissues including pancreatic islets, adipose tissue, stomach, small intestine, heart, bone, lung, kidney, testis, adrenal cortex, pituitary, endothelial cells, trachea, spleen, thymus, thyroid and brain.


Consistent with its biological function as incretin hormone, the pancreatic beta cell express the highest levels of the receptor for GIP in humans. There is some clinical evidence that the GIP-receptor mediated signaling could be impaired in patients with T2DM but the impairment of GIP-action is shown to be reversible and could be restored with improvement of the diabetic status. Of note, the stimulation of insulin secretion by both incretin hormones, GIP and GLP-1, is strictly glucose-dependent ensuring a fail-safe mechanism associated with a low risk for hypoglycemia.


At the beta cell level, GLP-1 and GIP have been shown to promote glucose sensitivity, neogenesis, proliferation, transcription of proinsulin and hypertrophy, as well as antiapoptosis. A peptide with dual agonistic activity for the GLP-1 and the GIP receptor could be anticipated to have additive or synergistic anti-diabetic benefit. Other relevant effects of GLP-1 beyond the pancreas include delayed gastric emptying, increased satiety, decreased food intake, reduction of body weight, as well as neuroprotective and cardioprotective effects. In patients with type 2 diabetes, such extrapancreatic effects could be particularly important considering the high rates of comorbidities like obesity and cardiovascular disease. Further GIP actions in peripheral tissues beyond the pancreas comprise increased bone formation and decreased bone resorption as well as neuroprotective effects which might be beneficial for the treatment of osteoporosis and cognitive defects like Alzheimer's disease.


Glucagon is a 29-amino acid peptide hormone that is produced by pancreatic alpha cells and released into the bloodstream when circulating glucose is low. An important physiological role of glucagon is to stimulate glucose output in the liver, which is a process providing the major counterregulatory mechanism for insulin in maintaining glucose homeostasis in vivo.


Glucagon receptors are however also expressed in extrahepatic tissues such as kidney, heart, adipocytes, lymphoblasts, brain, retina, adrenal gland and gastrointestinal tract, suggesting a broader physiological role beyond glucose homeostasis. Accordingly, recent studies have reported that glucagon has therapeutically positive effects on energy management, including stimulation of energy expenditure and thermogenesis, accompanied by reduction of food intake and body weight loss. Altogether, stimulation of glucagon receptors might be useful in the treatment of obesity and the metabolic syndrome.


Oxyntomodulin is a peptide hormone consisting of glucagon with a C-terminal extension encompassing eight amino acids. Like GLP-1 and glucagon, it is preformed in preproglucagon and cleaved and secreted in a tissue-specific manner by endocrinal cells of the small bowel. Oxyntomodulin is known to stimulate both, the receptors for GLP-1 and glucagon and is therefore the prototype of a dual agonist.


As GLP-1 and GIP are known for its anti-diabetic effects, GLP-1 and glucagon are both known for their food intake-suppressing effects and glucagon is also a mediator of additional energy expenditure, it is conceivable that a combination of the activities of the two hormones in one molecule can yield a powerful medication for treatment of the metabolic syndrome and in particular its components diabetes and obesity.


Accordingly, the compounds of the invention may be used for treatment of glucose intolerance, insulin resistance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or any combination of these individual disease components.


In addition, they may be used for control of appetite, feeding and calory intake, increase of energy expenditure, prevention of weight gain, promotion of weight loss, reduction of excess body weight and altogether treatment of obesity, including morbid obesity.


Further disease states and health conditions which could be treated with the compounds of the invention are obesity-linked inflammation, obesity-linked gallbladder disease and obesity-induced sleep apnea.


Although all these conditions could be associated directly or indirectly with obesity, the effects of the compounds of the invention may be mediated in whole or in part via an effect on body weight, or independent thereof.


Further diseases to be treated are neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, or other degenerative diseases as described above.


Compared to GLP-1, glucagon and oxyntomodulin, exendin-4 has beneficial physicochemical properties, such as solubility and stability in solution and under physiological conditions (including enzymatic stability towards degradation by enzymes, such as DPP-4 or NEP), which results in a longer duration of action in vivo. Therefore, exendin-4 might serve as good starting scaffold to obtain exendin-4 analogues with dual or even triple pharmacologies, e.g., GLP-1/Glucagon and optionally in addition GIP agonism.


Nevertheless, also exendin-4 has been shown to be chemically labile due to methionine oxidation in position 14 as well as deamidation and isomerization of asparagine in position 28. Therefore, stability might be further improved by substitution of methionine at position 14 and the avoidance of sequences that are known to be prone to degradation via aspartimide formation, especially Asp-Gly or Asn-Gly at positions 28 and 29.


Pharmaceutical Compositions


The term “pharmaceutical composition” indicates a mixture containing ingredients that are compatible when mixed and which may be administered. A pharmaceutical composition may include one or more medicinal drugs. Additionally, the pharmaceutical composition may include carriers, buffers, acidifying agents, alkalizing agents, solvents, adjuvants, tonicity adjusters, emollients, expanders, preservatives, physical and chemical stabilizers e.g. surfactants, antioxidants and other components, whether these are considered active or inactive ingredients. Guidance for the skilled in preparing pharmaceutical compositions may be found, for example, in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro A. R., 2000, Lippencott Williams & Wilkins and in R. C. Rowe et al (Ed), Handbook of Pharmaceutical Excipients, PhP, May 2013 update.


The exendin-4 peptide derivatives of the present invention, or salts thereof, are administered in conjunction with an acceptable pharmaceutical carrier, diluent, or excipient as part of a pharmaceutical composition. A “pharmaceutically acceptable carrier” is a carrier which is physiologically acceptable (e.g. physiologically acceptable pH) while retaining the therapeutic properties of the substance with which it is administered. Standard acceptable pharmaceutical carriers and their formulations are known to one skilled in the art and described, for example, in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro A. R., 2000, Lippencott Williams & Wilkins and in R. C. Rowe et al (Ed), Handbook of Pharmaceutical excipients, PhP, May 2013 update. One exemplary pharmaceutically acceptable carrier is physiological saline solution.


In one embodiment carriers are selected from the group of buffers (e.g. citrate/citric acid), acidifying agents (e.g. hydrochloric acid), alkalizing agents (e.g. sodium hydroxide), preservatives (e.g. phenol), co-solvents (e.g. polyethylene glycol 400), tonicity adjusters (e.g. mannitol), stabilizers (e.g. surfactant, antioxidants, amino acids).


Concentrations used are in a range that is physiologically acceptable.


Acceptable pharmaceutical carriers or diluents include those used in formulations suitable for oral, rectal, nasal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and transdermal) administration. The compounds of the present invention will typically be administered parenterally.


The term “pharmaceutically acceptable salt” means salts of the compounds of the invention which are safe and effective for use in mammals. Pharmaceutically acceptable salts may include, but are not limited to, acid addition salts and basic salts. Examples of acid addition salts include chloride, sulfate, hydrogen sulfate, (hydrogen) phosphate, acetate, citrate, tosylate or mesylate salts. Examples of basic salts include salts with inorganic cations, e.g. alkaline or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts and salts with organic cations such as amine salts. Further examples of pharmaceutically acceptable salts are described in Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro A. R., 2000, Lippencott Williams & Wilkins or in Handbook of Pharmaceutical Salts, Properties, Selection and Use, e.d. P. H. Stahl, C. G. Wermuth, 2002, jointly published by Verlag Helvetica Chimica Acta, Zurich, Switzerland, and Wiley-VCH, Weinheim, Germany.


The term “solvate” means complexes of the compounds of the invention or salts thereof with solvent molecules, e.g. organic solvent molecules and/or water.


In the pharmaceutical composition, the exendin-4 derivative can be in monomeric or oligomeric form.


The term “therapeutically effective amount” of a compound refers to a nontoxic but sufficient amount of the compound to provide the desired effect. The amount of a compound of the formula I necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation For example the “therapeutically effective amount” of a compound of the formula (I) is about 0.01 to 50 mg/dose, preferably 0.1 to 10 mg/dose.


Pharmaceutical compositions of the invention are those suitable for parenteral (for example subcutaneous, intramuscular, intradermal or intravenous), oral, rectal, topical and peroral (for example sublingual) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula I used in each case.


Suitable pharmaceutical compositions may be in the form of separate units, for example capsules, tablets and powders in vials or ampoules, each of which contains a defined amount of the compound; as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. It may be provided in single dose injectable form, for example in the form of a pen. The compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact.


In certain embodiments the pharmaceutical composition may be provided together with a device for application, for example together with a syringe, an injection pen or an autoinjector. Such devices may be provided separate from a pharmaceutical composition or prefilled with the pharmaceutical composition.


Combination Therapy


The compounds of the present invention, dual agonists for the GLP-1 and glucagon receptors, can be widely combined with other pharmacologically active compounds, such as all drugs mentioned in the Rote Liste 2013, e.g. with all weight-reducing agents or appetite suppressants mentioned in the Rote Liste 2013, chapter 1, all lipid-lowering agents mentioned in the Rote Liste 2013, chapter 58, all antihypertensives and nephroprotectives, mentioned in the Rote Liste 2013, or all diuretics mentioned in the Rote Liste 2013, chapter 36.


The active ingredient combinations can be used especially for a synergistic improvement in action. They can be applied either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. When the active ingredients are administered by separate administration of the active ingredients, this can be done simultaneously or successively.


Most of the active ingredients mentioned hereinafter are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2011.


Other active substances which are suitable for such combinations include in particular those which for example potentiate the therapeutic effect of one or more active substances with respect to one of the indications mentioned and/or which allow the dosage of one or more active substances to be reduced.


Therapeutic agents which are suitable for combinations include, for example, antidiabetic agents such as:


Insulin and Insulin derivatives, for example: Glargine/Lantus®, 270-330 U/mL of insulin glargine (EP 2387989 A), 300 U/mL of insulin glargine (EP 2387989 A), Glulisin/Apidra®, Detemir/Levemir®, Lispro/Humalog®/Liprolog®, Degludec/DegludecPlus, Aspart, basal insulin and analogues (e.g. LY-2605541, LY2963016, NN1436), PEGylated insulin Lispro, Humulin®, Linjeta, SuliXen®, NN1045, Insulin plus Symlin, PE0139, fast-acting and short-acting insulins (e.g. Linjeta, PH20, NN1218, HinsBet), (APC-002)hydrogel, oral, inhalable, transdermal and sublingual insulins (e.g. Exubera®, Nasulin®, Afrezza, Tregopil, TPM 02, Capsulin, Oral-Lyn®, Cobalamin® oral insulin, ORMD-0801, NN1953, NN1954, NN1956, VIAtab, Oshadi oral insulin). Additionally included are also those insulin derivatives which are bonded to albumin or another protein by a bifunctional linker.


GLP-1, GLP-1 analogues and GLP-1 receptor agonists, for example: Lixisenatide/AVE0010/ZP10/Lyxumia, Exenatide/Exendin-4/Byetta/Bydureon/ITCA 650/AC-2993, Liraglutide/Victoza, Semaglutide, Taspoglutide, Syncria/Albiglutide, Dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.


DPP-4 inhibitors, for example: Alogliptin/Nesina, Trajenta/Linagliptin/BI-1356/Ondero/Trajenta/Tradjenta/Trayenta/Tradzenta, Saxagliptin/Onglyza, Sitagliptin/Januvia/Xelevia/Tesave/Janumet/Velmetia, Galvus/Vildagliptin, Anagliptin, Gemigliptin, Teneligliptin, Melogliptin, Trelagliptin, DA-1229, Omarigliptin/MK-3102, KM-223, Evogliptin, ARI-2243, PBL-1427, Pinoxacin.


SGLT2 inhibitors, for example: Invokana/Canaglifozin, Forxiga/Dapagliflozin, Remoglifozin, Sergliflozin, Empagliflozin, Ipragliflozin, Tofogliflozin, Luseogliflozin, LX-4211, Ertuglifozin/PF-04971729, RO-4998452, EGT-0001442, KGA-3235/DSP-3235, LIK066, SBM-TFC-039,


Biguanides (e.g. Metformin, Buformin, Phenformin), Thiazolidinediones (e.g. Pioglitazone, Rivoglitazone, Rosiglitazone, Troglitazone), dual PPAR agonists (e.g. Aleglitazar, Muraglitazar, Tesaglitazar), Sulfonylureas (e.g. Tolbutamide, Glibenclamide, Glimepiride/Amaryl, Glipizide), Meglitinides (e.g. Nateglinide, Repaglinide, Mitiglinide), Alpha-glucosidase inhibitors (e.g. Acarbose, Miglitol, Voglibose), Amylin and Amylin analogues (e.g. Pramlintide, Symlin).


GPR119 agonists (e.g. GSK-263A, PSN-821, MBX-2982, APD-597, ZYG-19, DS-8500), GPR40 agonists (e.g. Fasiglifam/TAK-875, TUG-424, P-1736, JTT-851, GW9508).


Other suitable combination partners are: Cycloset, inhibitors of 11-beta-HSD (e.g. LY2523199, BMS770767, RG-4929, BMS816336, AZD-8329, HSD-016, BI-135585), activators of glucokinase (e.g. TTP-399, AMG-151, TAK-329, GKM-001), inhibitors of DGAT (e.g. LCQ-908), inhibitors of protein tyrosinephosphatase 1 (e.g. Trodusquemine), inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrokinase, alpha2-antagonists, CCR-2 antagonists, SGLT-1 inhibitors (e.g. LX-2761).


One or more lipid lowering agents are also suitable as combination partners, such as for example: HMG-CoA-reductase inhibitors (e.g. Simvastatin, Atorvastatin), fibrates (e.g. Bezafibrate, Fenofibrate), nicotinic acid and the derivatives thereof (e.g. Niacin), PPAR-(alpha, gamma or alpha/gamma) agonists or modulators (e.g. Aleglitazar), PPAR-delta agonists, ACAT inhibitors (e.g. Avasimibe), cholesterol absorption inhibitors (e.g. Ezetimibe), Bile acid-binding substances (e.g. Cholestyramine), ileal bile acid transport inhibitors, MTP inhibitors, or modulators of PCSK9.


HDL-raising compounds such as: CETP inhibitors (e.g. Torcetrapib, Anacetrapid, Dalcetrapid, Evacetrapid, JTT-302, DRL-17822, TA-8995) or ABC1 regulators.


Other suitable combination partners are one or more active substances for the treatment of obesity, such as for example: Sibutramine, Tesofensine, Orlistat, antagonists of the cannabinoid-1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists (e.g. Velneperit), beta-3-agonists, leptin or leptin mimetics, agonists of the 5HT2c receptor (e.g. Lorcaserin), or the combinations of bupropione/naltrexone, bupropione/zonisamide, bupropione/phentermine or pramlintide/metreleptin.


Other suitable combination partners are:


Further gastrointestinal peptides such as Peptide YY 3-36 (PYY3-36) or analogues thereof, pancreatic polypeptide (PP) or analogues thereof.


Glucagon receptor agonists or antagonists, GIP receptor agonists or antagonists, ghrelin antagonists or inverse agonists, Xenin and analogues thereof.


Moreover, combinations with drugs for influencing high blood pressure, chronic heart failure or atherosclerosis, such as e.g.: Angiotensin II receptor antagonists (e.g. telmisartan, candesartan, valsartan, losartan, eprosartan, irbesartan, olmesartan, tasosartan, azilsartan), ACE inhibitors, ECE inhibitors, diuretics, beta-blockers, calcium antagonists, centrally acting hypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable.


In another aspect, this invention relates to the use of a compound according to the invention or a physiologically acceptable salt thereof combined with at least one of the active substances described above as a combination partner, for preparing a medicament which is suitable for the treatment or prevention of diseases or conditions which can be affected by binding to the receptors for GLP-1 and glucagon and by modulating their activity. This is preferably a disease in the context of the metabolic syndrome, particularly one of the diseases or conditions listed above, most particularly diabetes or obesity or complications thereof.


The use of the compounds according to the invention, or a physiologically acceptable salt thereof, in combination with one or more active substances may take place simultaneously, separately or sequentially.


The use of the compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may take place simultaneously or at staggered times, but particularly within a short space of time. If they are administered simultaneously, the two active substances are given to the patient together; if they are used at staggered times, the two active substances are given to the patient within a period of less than or equal to 12 hours, but particularly less than or equal to 6 hours.


Consequently, in another aspect, this invention relates to a medicament which comprises a compound according to the invention or a physiologically acceptable salt of such a compound and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and/or diluents.


The compound according to the invention, or physiologically acceptable salt or solvate thereof, and the additional active substance to be combined therewith may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as so-called kit-of-parts.


Methods


Abbreviations employed are as follows:

  • AA amino acid
  • cAMP cyclic adenosine monophosphate
  • Boc tert-butyloxycarbonyl
  • BOP (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate
  • BSA bovine serum albumin
  • tBu tertiary butyl
  • Dde 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl
  • ivDde 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)3-methyl-butyl
  • DIC N,N′-diisopropylcarbodiimide
  • DIPEA N,N-diisopropylethylamine
  • DMEM Dulbecco's modified Eagle's medium
  • DMF dimethyl formamide
  • EDT ethanedithiol
  • FBS fetal bovine serum
  • Fmoc fluorenylmethyloxycarbonyl
  • HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
  • HBSS Hanks' Balanced Salt Solution
  • HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate
  • HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
  • HOBt 1-hydroxybenzotriazole
  • HOSu N-hydroxysuccinimide
  • HPLC High Performance Liquid Chromatography
  • HTRF Homogenous Time Resolved Fluorescence
  • IBMX 3-isobutyl-1-methylxanthine
  • LC/MS Liquid Chromatography/Mass Spectrometry
  • Palm palmitoyl
  • PBS phosphate buffered saline
  • PEG polyethylene glycole
  • PK pharmacokinetic
  • RP-HPLC reversed-phase high performance liquid chromatography
  • TFA trifluoroacetic acid
  • Trt trityl
  • UPLC Ultra Performance Liquid Chromatography
  • UV ultraviolet


    General Synthesis of Peptidic Compounds


    Materials:


Different Rink-Amide resins (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin, Merck Biosciences; 4-[(2,4-Dimethoxyphenyl)(Fmoc-amino)methyl]phenoxy acetamido methyl resin, Agilent Technologies) were used for the synthesis of peptide amides with loadings in the range of 0.3-0.4 mmol/g.


Fmoc protected natural amino acids were purchased from Protein Technologies Inc., Senn Chemicals, Merck Biosciences, Novabiochem, Iris Biotech, Nagase or Bachem. The following standard amino acids were used throughout the syntheses: Fmoc-L-Ala-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Cys(Trt)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-L-His(Trt)-OH, Fmoc-L-Ile-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Met-OH, Fmoc-L-Phe-OH, Fmoc-L-Pro-OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-L-Tyr(tBu)-OH, Fmoc-L-Val-OH.


In addition, the following special amino acids were purchased from the same suppliers as above: Fmoc-L-Lys(ivDde)-OH, Fmoc-Aib-OH, Fmoc-D-Ser(tBu)-OH, Fmoc-D-Ala-OH, Boc-L-His(Boc)-OH (available as toluene solvate) and Boc-L-His(Trt)-OH, Fmoc-L-Nle-OH, Fmoc-L-Met(O)-OH, Fmoc-L-Met(O2)-OH, Fmoc-(S)MeLys(Boc)-OH, Fmoc-(R)MeLys(Boc)-OH, Fmoc-(S)MeOrn(Boc)-OH and Boc-L-Tyr(tBu)-OH.


The solid phase peptide syntheses were performed for example on a Prelude Peptide Synthesizer (Protein Technologies Inc) or similar automated synthesizer using standard Fmoc chemistry and HBTU/DIPEA activation. DMF was used as the solvent. Deprotection: 20% piperidine/DMF for 2×2.5 min. Washes: 7×DMF. Coupling 2:5:10 200 mM AA/500 mM HBTU/2M DIPEA in DMF 2× for 20 min. Washes: 5×DMF.


All the peptides that had been synthesized were cleaved from the resin with King's cleavage cocktail consisting of 82.5% TFA, 5% phenol, 5% water, 5% thioanisole, 2.5% EDT. The crude peptides were then precipitated in diethyl or diisopropyl ether, centrifuged, and lyophilized. Peptides were analyzed by analytical HPLC and checked by ESI mass spectrometry. Crude peptides were purified by a conventional preparative HPLC purification procedure.


Analytical HPLC/UPLC


Method A: detection at 215 nm




  • column: Aeris Peptide, 3.6 μm, XB-C18 (250×4.6 mm) at 60° C.

  • solvent: H2O+0.1% TFA: ACN+0.1% TFA (flow 1.5 ml/min)

  • gradient: 90:10 (0 min) to 90:10 (3 min) to 10:90 (43 min) to 10:90 (48 min) to 90:10 (49 min) to 90:10 (50 min)


    Method B: detection at 220 nm

  • column: Zorbax, 5 μm, C18 (250×4.6 mm) at 25° C.

  • solvent: H2O+0.1% TFA: 90% ACN+10% H2O+0.1% TFA (flow 1.0 ml/min)

  • gradient: 100:0 (0 min) to 98:2 (2 min) to 30:70 (15 min) to 5:95 (20 min) to 0:100 (25 min) to 0:100 (30 min) to 98:2 (32 min) to 98:2 (35 min)


    Method C1: detection at 210-225 nm, optionally coupled to a mass analyser Waters LCT Premier, electrospray positive ion mode

  • column: Waters ACQUITY UPLC® BEH™ C18 1.7 μm (150×2.1 mm) at 50° C.

  • solvent: H2O+1% FA: ACN+1% FA (flow 0.5 ml/min)

  • gradient: 95:5 (0 min) to 95:5 (1.80 min) to 80:20 (1.85 min) to 80:20 (3 min) to 60:40 (23 min) to 25:75 (23.1 min) to 25:75 (25 min) to 95:5 (25.1 min) to 95:5 (30 min)


    Method C2: detection at 210-225 nm, optionally coupled to a mass analyser Waters LCT Premier, electrospray positive ion mode

  • column: Waters ACQUITY UPLC® BEH™ C18 1.7 μm (150×2.1 mm) at 50° C.

  • solvent: H2O+1% FA: ACN+1% FA (flow 0.6 ml/min)

  • gradient: 95:5 (0 min) to 95:5 (1 min) to 65:35 (2 min) to 65:35 (3 min) to 45:55 (23 min) to 25:75 (23.1 min) to 25:75 (25 min) to 95:5 (25.1 min) to 95:5 (30 min)


    Method C3: detection at 210-225 nm, optionally coupled to a mass analyser Waters LCT Premier, electrospray positive ion mode

  • column: Waters ACQUITY UPLC® BEH™ C18 1.7 μm (150×2.1 mm) at 50° C.

  • solvent: H2O+1% FA: ACN+1% FA (flow 1 ml/min)

  • gradient: 95:5 (0 min) to 95:5 (1 min) to 65:35 (2 min) to 65:35 (3 min) to 45:55 (20 min) to 2:98 (20.1 min) to 2:98 (25 min) to 95:5 (25.1 min) to 95:5 (30 min)


    Method C4:


    detection at 210-225 nm, optionally coupled to a mass analyser Waters LCT Premier, electrospray positive ion mode

  • column: Waters ACQUITY UPLC® BEH™ C18 1.7 μm (150×2.1 mm) at 50° C.

  • solvent: H2O+1% FA: ACN+1% FA (flow 1 ml/min)

  • gradient: 95:5 (0 min) to 95:5 (1.80 min) to 80:20 (1.85 min) to 80:20 (3 min) to 60:40 (23 min) to 2:98 (23.1 min) to 2:98 (25 min) to 95:5 (25.1 min) to 95:5 (30 min)


    Method D: detection at 214 nm

  • column: Waters X-Bridge C18 3.5 μm 2.1×150 mm

  • solvent: H2O+0.5% TFA: ACN (flow 0.55 ml/min)

  • gradient: 90:10 (0 min) to 40:60 (5 min) to 1:99 (15 min)


    Method E: detection at 210-225 nm, optionally coupled to a mass analyser Waters LCT Premier, electrospray positive ion mode

  • column: Waters ACQUITY UPLC® BEH™ C18 1.7 μm (150×2.1 mm) at 50° C.

  • solvent: H2O+1% FA: ACN+1% FA (flow 0.9 ml/min)

  • gradient: 95:5 (0 min) to 95:5 (2 min) to 35:65 (3 min) to 65:35 (23.5 min) to 5:95 (24 min) to 95:5 (26 min) to 95:5 (30 min)


    General Preparative HPLC Purification Procedure:



The crude peptides were purified either on an Äkta Purifier System or on a Jasco semiprep HPLC System. Preparative RP-C18-HPLC columns of different sizes and with different flow rates were used depending on the amount of crude peptide to be purified. Acetonitrile+0.05 to 0.1% TFA (B) and water+0.05 to 0.1% TFA (A) were employed as eluents. Alternatively, a buffer system consisting of acetonitrile and water with minor amounts of acetic acid was used. Product-containing fractions were collected and lyophilized to obtain the purified product, typically as TFA or acetate salt.


Solubility and Stability-Testing of Exendin-4 Derivatives


Prior to the testing of solubility and stability of a peptide batch, its content was determined. Therefore, two parameters were investigated, its purity (HPLC-UV) and the amount of salt load of the batch (ion chromatography).


For solubility testing, the target concentration was 1.0 mg/mL pure compound. Therefore, solutions from solid samples were prepared in different buffer systems with a concentration of 1.0 mg/mL compound based on the previously determined content. HPLC-UV was performed after 2 h of gentle agitation from the supernatant, which was obtained by 20 min of centrifugation at 4000 rpm.


The solubility was then determined by comparison with the UV peak areas obtained with a stock solution of the peptide at a concentration of 2 mg/mL in pure water or a variable amount of acetonitrile (optical control that all of the compound was dissolved). This analysis also served as starting point (t0) for the stability testing.


For stability testing, an aliquot of the supernatant obtained for solubility was stored for 7 days at 25° C. or 40° C. After that time course, the sample was centrifuged for 20 min at 4000 rpm and the supernatant was analysed with HPLC-UV.


For determination of the amount of the remaining peptide, the peak areas of the target compound at t0 and t7 were compared, resulting in “% remaining peptide”, following the equation

% remaining peptide=[(peak area peptide t7)×100]/peak area peptide t0.


The amount of soluble degradation products was calculated from the comparison of the sum of the peak areas from all observed impurities reduced by the sum of peak areas observed at t0 (i.e. to determine the amount of newly formed peptide-related species). This value was given in percentual relation to the initial amount of peptide at t0, following the equation:

% soluble degradation products={[(peak area sum of impurities t7)−(peak area sum of impurities t0)]×100}/peak area peptide t0


The potential difference from the sum of “% remaining peptide” and “% soluble degradation products” to 100% reflects the amount of peptide which did not remain soluble upon stress conditions following the equation

% precipitate=100−([% remaining peptide]+[% soluble degradation products])


This precipitate includes non-soluble degradation products, polymers and/or fibrils, which have been removed from analysis by centrifugation.


The chemical stability is expressed as “% remaining peptide”.


Anion Chromatography


Instrument: Dionex ICS-2000, pre/column: Ion Pac AG-18 2×50 mm (Dionex)/AS18 2×250 mm (Dionex), eluent: aqueous sodium hydroxide, flow: 0.38 mL/min, gradient: 0-6 min: 22 mM KOH, 6-12 min: 22-28 mM KOH, 12-15 min: 28-50 mM KOH, 15-20 min: 22 mM KOH, suppressor: ASRS 300 2 mm, detection: conductivity.


As HPLC/UPLC method, method D or E has been used.


In Vitro Cellular Assays for GLP-1 Receptor, Glucagon Receptor and GIP Receptor Efficacy


Agonism of compounds for the receptors was determined by functional assays measuring cAMP response of HEK-293 cell lines stably expressing human GIP, GLP-1 or glucagon receptor.


cAMP content of cells was determined using a kit from Cisbio Corp. (cat. no. 62AM4PEC) based on HTRF (Homogenous Time Resolved Fluorescence). For preparation, cells were split into T175 culture flasks and grown overnight to near confluency in medium (DMEM/10% FBS). Medium was then removed and cells washed with PBS lacking calcium and magnesium, followed by proteinase treatment with accutase (Sigma-Aldrich cat. no. A6964). Detached cells were washed and resuspended in assay buffer (1×HBSS; 20 mM HEPES, 0.1% BSA, 2 mM IBMX) and cellular density determined. They were then diluted to 400000 cells/ml and 25 μl-aliquots dispensed into the wells of 96-well plates. For measurement, 25 μl of test compound in assay buffer was added to the wells, followed by incubation for 30 minutes at room temperature. After addition of HTRF reagents diluted in lysis buffer (kit components), the plates were incubated for 1 hr, followed by measurement of the fluorescence ratio at 665/620 nm. In vitro potency of agonists was quantified by determining the concentrations that caused 50% activation of maximal response (EC50).


Glucose Lowering in Female Diabetic dbdb-Mice


Female diabetic dbdb-mice (BKS.Cg−+Leprdb/+Leprdb/OlaHsd) 10 weeks of age at study start were used. Mice were habituated to feeding and housing conditions for at least 2 weeks. 7 days prior to study start, HbA1c were determined to allocate mice to groups, aiming to spread low, medium and high HbA1c-values and in consequence the group-means (n=8), as equally as possible. On the day of study, food was removed, directly before sampling for baseline glucose assessment (t=0 min). Immediately afterwards, compounds or vehicle (phosphor buffered saline, PBS) were administered subcutaneously, 100 μg/kg, 10 ml/kg. Afterwards, blood samples were drawn by tail tip incision at 15, 30, 60, 90, 120, 150, 180, 240, 360, 480 min and 24 h. Food was re-offered after the 480 min-sampling.


Data were analysed by 2-W-ANOVA on repeated measurements, followed by Dunnett's test as post-hoc assessment, level of significance p<0.05.


EXAMPLES

The invention is further illustrated by the following examples.


Example 1
Synthesis of SEQ ID NO: 8

The solid phase synthesis was carried out on a Rink-resin (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin) with a loading of 0.38 mmol/g, 75-150 μm from the company Agilent Technologies. The Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. The peptide was cleaved from the resin with King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266). The crude product was purified via preparative HPLC on a Waters column (XBridge, BEH130, Prep C18 5 μM) using an acetonitrile/water gradient (both buffers with 0.1% TFA).


Finally, the molecular mass of the purified peptide was confirmed by LC-MS.


Example 2
Synthesis of SEQ ID NO: 9

The solid phase synthesis was carried out on a Rink-resin (4-(2′,4′-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin) with a loading of 0.38 mmol/g, 75-150 μm from the company Agilent Technologies. The Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. The peptide was cleaved from the resin with King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266). The crude product was purified via preparative HPLC on a Waters column (XBridge, BEH130, Prep C18 5 μM) using an acetonitrile/water gradient (both buffers with 0.1% TFA).


Finally, the molecular mass of the purified peptide was confirmed by LC-MS.


In an analogous way, the other peptides listed in Table 2 were synthesized.









TABLE 2







list of synthesized peptides and comparison of calculated vs. found


molecular weight











found


SEQ ID NO
calc. Mass
mass





5
4140.6
4140.9


6
4104.6
4103.7


7
4152.6
4151.7


8
4106.6
4106.8


9
4106.6
4106.6









Example 3
Chemical Stability and Solubility

Solubility and chemical stability of peptidic compounds were assessed as described in Methods. The results are given in Table 3.









TABLE 3







Chemical stability and solubility









SEQ ID
Stability
solubility [mg/ml]












NO
pH4.5
pH7.4
Temperature
pH4.5
pH7.4















1
100
77.5
25° C.
933.6
>1000


5
92.6
96.5
40° C.
>1000
>1000









Example 4
In Vitro Data on GLP-1 and Glucagon Receptor

Potencies of peptidic compounds at the GLP-1 and glucagon receptors were determined by exposing cells expressing human glucagon receptor (hGlucagon R) or human GLP-1 receptor (hGLP-1 R) to the listed compounds at increasing concentrations and measuring the formed cAMP as described in Methods.


The results are shown in Table 4:









TABLE 4







EC50 values of exendin-4 derivatives at GLP-1 and Glucagon receptors


(indicated in pM)










EC50
EC50


SEQ ID NO
hGLP-1R
hGlucagon-R





5
3.5
12.1


6
2.2
25.7


7
6.5
11.9


8
2.0
53.9


9
1.8
20.0
















TABLE 5







Sequences








SEQ



ID
sequence





1
H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-



I-E-W-L-K-N-G-G-P-S-S-G-A-P-P-P-S-NH2





2
H-A-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-



I-A-W-L-V-K-G-R-NH2





3
H-S-Q-G-T-F-T-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-



V-Q-W-L-M-N-T





4
H-A-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K((S)-



4-Carboxy-4-hexadecanoylamino-butyryl-)-



E-F-I-A-W-L-V-R-G-R-G





5
H-dSer-Q-G-T-F-T-S-D-L-S-K-L-L-D-E-Q-R-A-K-D-



F-I-E-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2





6
H-Aib-H-G-T-F-T-S-D-L-S-K-L-L-D-E-Q-L-A-K-D-



F-I-E-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2





7
H-dSer-Q-G-T-F-T-S-D-L-S-K-L-L-D-E-Q-R-A-K-D-



F-I-E-W-L-I-A-G-G-P-V-S-G-A-P-P-P-S-NH2





8
H-dSer-H-G-T-F-T-S-D-L-S-K-L-L-D-E-Q-L-A-K-D-



F-I-E-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2





9
H-S-H-G-T-F-T-S-D-L-S-K-L-L-D-E-Q-L-A-K-D-F-



I-E-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S-NH2








Claims
  • 1. A peptidic compound of formula (I): R1—Z—R2  (I),or a salt or solvate thereof,wherein Z is a peptide moiety of formula (II):
  • 2. The compound, salt, or solvate of claim 1, which is a glucagon-like peptide (GLP-1) and glucagon receptor agonist.
  • 3. The compound, salt, or solvate of claim 1, wherein R2 is —NH2.
  • 4. The compound, salt, or solvate of claim 1, wherein the peptidic compound has a relative activity of at least 0.1% compared to that of natural glucagon at the glucagon receptor.
  • 5. The compound, salt, or solvate of claim 1, wherein the peptidic compound exhibits a relative activity of at least 0.1% compared to that of GLP-1(7-36) at the GLP-1 receptor.
  • 6. The compound, salt, or solvate claim 1, wherein X2 is D-Ser,X3 is an amino acid residue selected from Gln and His,X18 is an amino acid residue selected from Arg and Leu, andX32 is an amino acid residue selected from Ser and Val.
  • 7. The compound, salt, or solvate of claim 1, wherein X2 is an amino acid residue selected from Ser, D-Ser, and Aib,X3 is His,X18 is an amino acid residue selected from Arg and Leu, andX32 is an amino acid residue selected from Ser and Val.
  • 8. The compound, salt, or solvate of claim 1, wherein X2 is D-Ser,X3 is Gln,X18 is Arg, andX32 is an amino acid residue selected from Ser and Val.
  • 9. The compound, salt, or solvate of claim 1, wherein X2 is an amino acid residue selected from Ser, D-Ser, and Aib,X3 is an amino acid residue selected from Gln and His,X18 is an amino acid residue selected from Arg and Leu, andX32 is Ser.
  • 10. The compound, salt, or solvate of claim 1, wherein the compound is the peptide of any one of SEQ ID NOs: 5-9, or a salt or solvate thereof.
  • 11. A pharmaceutical composition comprising the compound of claim 1, or a salt or solvate thereof.
  • 12. The pharmaceutical composition of claim 11, together with at least one pharmaceutically acceptable carrier.
  • 13. The pharmaceutical composition of claim 11, further comprising at least one additional therapeutically active agent, wherein the additional therapeutically active agent is selected from the group consisting of: insulin and insulin derivatives selected from the group consisting of insulin glargine, insulin glusiline, insulin detemir, insulin lispro, insulin degludec, insulin aspart, basal insulin and analogues thereof, pegylated insulin, recombinant human insulin, polysialated insulins, long-acting insulin, NN1045, insulin in combination with pramlintide, PE0139, fast-acting and short-acting insulins, insulin hydrogel, oral insulin, inhalable insulin, transdermal insulin and sublingual insulin, and insulin derivatives which are bonded to albumin or another protein by a bifunctional linker;GLP-1; GLP-1 analogues; GLP-1 receptor agonists selected from the group consisting of lixisenatide, exenatide, ITCA 650, AC-2993, liraglutide, semaglutide, taspoglutide, albiglutide, dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide, HM-11260C, CM-3, ORMD-0901, NN-9924, NN-9926, NN-9927, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, xtenylated exenatide, xtenylated glucagon, and polymer bound derivatives thereof;dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists; dual GLP-1/glucagon receptor agonists; protein YY3-36 (PYY3-36); pancreatic polypeptide; glucagon receptor agonists; GIP receptor agonists or antagonists; ghrelin antagonists or inverse agonists; xenin; dipeptidyl peptidase IV (DPP-IV) inhibitors; sodium glucose cotransporter 2 (SGLT2) inhibitors; dual SGLT2/SGLT1 inhibitors; biguanides; thiazolidinediones; dual peroxisome proliferator-activated receptor (PPAR) agonists; sulfonylureas; meglitinides; alpha-glucosidase inhibitors; amylin and pramlintide; G protein-coupled receptor 119 (GPR119) agonists; GPR40 agonists; GPR120 agonists; GPR142 agonists; systemic or low-absorbable transmembrane G protein-coupled receptor 5 (TGR5) agonists; bromocriptine mesylate; inhibitors of 11-beta-hydroxysteroid dehydrogenase (HSD); activators of glucokinase; inhibitors of diacylglycerol acyltransferase (DGAT); inhibitors of protein tyrosinephosphatase 1; inhibitors of glucose-6-phosphatase; inhibitors of fructose-1,6-bisphosphatase; inhibitors of glycogen phosphorylase; inhibitors of phosphoenol pyruvate carboxykinase; inhibitors of glycogen synthase kinase; inhibitors of pyruvate dehydrogenase kinase; alpha2-antagonists; C-C motif receptor (CCR-2) antagonists; modulators of glucose transporter-4; somatostatin receptor 3 agonists; 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)-reductase inhibitors; fibrates; nicotinic acid and derivatives thereof; nicotinic acid receptor 1 agonists; PPAR-alpha, gamma, or alpha/gamma agonists or modulators; PPAR-delta agonists; acyl-CoA cholesterol acyltransferase (ACAT) inhibitors; cholesterol absorption inhibitors; bile acid-binding substances; ileal bile acid transporter (IBAT) inhibitors; microsomal triglyceride transfer protein (MTP) inhibitors; modulators of proprotein convertase subtilisin/kinexin type 9 (PCSK9); low-density lipoprotein (LDL) receptor up-regulators by liver selective thyroid hormone receptor β agonists; high-density lipoprotein (HDL)-raising compounds; lipid metabolism modulators; phospholipase A2 (PLA2) inhibitors; apolipoprotein A1 (ApoA-1) enhancers; thyroid hormone receptor agonists; cholesterol synthesis inhibitors; omega-3 fatty acids and derivatives thereof;substances for the treatment of obesity selected from the group consisting of sibutramine, tesofensine, tetrahydrolipstatin, cannabinoid-1 (CB-1) receptor antagonists, melanin-concentrating hormone-1 (MCH-1) antagonists, melanocortin 4 (MC4) receptor agonists and partial agonists, neuropeptide Y5 (NPY5) or NPY2 antagonists, NPY4 agonists, beta-3-agonists, leptin or leptin mimetics, agonists of the 5-hydroxy tryptophan 2c (5HT2c) receptor, combinations of bupropione/naltrexone, combinations of bupropione/zonisamide, combinations of bupropione/phentermine, combinations of pramlintide/metreleptin, and combinations of phentermine/topiramate;lipase inhibitors; angiogenesis inhibitors; H3 antagonists; Agouti-related protein (AgRP) inhibitors; triple monoamine uptake inhibitors; methionine aminopeptidase type 2 (MetAP2) inhibitors; nasal formulation of the calcium channel blocker diltiazem; antisense molecules against production of fibroblast growth factor receptor 4; prohibitin targeting peptide-1; and drugs for influencing high blood pressure, chronic heart failure, or atherosclerosis selected from the group consisting of angiotensin II receptor antagonists, angiotensin-converting-enzyme (ACE) inhibitors, endothelin-converting-enzyme (ECE) inhibitors, diuretics, beta-blockers, calcium antagonists, centrally acting hypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, and thrombocyte aggregation inhibitors.
  • 14. A method of treating a disease or disorder comprising administering to a patient in need thereof the pharmaceutical composition of claim 11, wherein the disease or disorder is selected from the group consisting of hyperglycemia, type 2 diabetes, type 1 diabetes, and obesity.
  • 15. The method of claim 14, wherein the disease or disorder is selected from the group consisting of hyperglycemia, type 2 diabetes, and obesity.
  • 16. A method of treating hyperglycemia, type 2 diabetes, or obesity in a patient, the method comprising administering to the patient an effective amount of at least one compound of formula I according to claim 1 and an effective amount of at least one additional compound for treating hyperglycemia, type 2 diabetes, or obesity.
  • 17. The method of claim 16, wherein the effective amounts of the at least one compound of formula I and of the at least one additional compound are administered to the patient simultaneously.
  • 18. The method of claim 16, wherein the effective amount of the at least one compound of formula I and of the at least one additional compound are administered to the patient sequentially.
  • 19. The method of claim 14, wherein the method delays the progression of impaired glucose tolerance (IGT) to type 2 diabetes or the progression of type 2 diabetes to insulin-requiring diabetes.
  • 20. The method of claim 14, wherein the method regulates appetite or induces satiety.
  • 21. A solvate of a compound of claim 1.
  • 22. A hydrate of a compound of claim 1.
Priority Claims (1)
Number Date Country Kind
13306717 Dec 2013 EP regional
US Referenced Citations (634)
Number Name Date Kind
5424286 Eng Jun 1995 A
5641757 Bornstein et al. Jun 1997 A
6284727 Kim et al. Sep 2001 B1
6329336 Bridon et al. Dec 2001 B1
6344180 Holst et al. Feb 2002 B1
6410511 L'Italien et al. Jun 2002 B2
6429197 Coolidge et al. Aug 2002 B1
6451974 Hansen Sep 2002 B1
6458924 Knudsen et al. Oct 2002 B2
6482799 Tusé et al. Nov 2002 B1
6506724 Hiles et al. Jan 2003 B1
6514500 Bridon et al. Feb 2003 B1
6528486 Larsen et al. Mar 2003 B1
6579851 Goeke et al. Jun 2003 B2
6593295 Bridon et al. Jul 2003 B2
6703359 Young et al. Mar 2004 B1
6706689 Coolidge et al. Mar 2004 B2
6723530 Drucker Apr 2004 B1
6821949 Bridon et al. Nov 2004 B2
6828303 Kim et al. Dec 2004 B2
6849714 Bridon et al. Feb 2005 B1
6858576 Young et al. Feb 2005 B1
6861236 Moll et al. Mar 2005 B2
6872700 Young et al. Mar 2005 B1
6884579 Holst et al. Apr 2005 B2
6887470 Bridon et al. May 2005 B1
6887849 Bridon et al. May 2005 B2
6894024 Coolidge et al. May 2005 B2
6902744 Kolterman et al. Jun 2005 B1
6924264 Prickett et al. Aug 2005 B1
6956026 Beeley et al. Oct 2005 B2
6969702 Bertilsson et al. Nov 2005 B2
6972319 Pan et al. Dec 2005 B1
6982248 Coolidge et al. Jan 2006 B2
6989366 Beeley et al. Jan 2006 B2
6998387 Goke et al. Feb 2006 B1
7056734 Egan et al. Jun 2006 B1
7056887 Coolidge et al. Jun 2006 B2
7105489 Hathaway et al. Sep 2006 B2
7105490 Beeley et al. Sep 2006 B2
7115569 Beeley et al. Oct 2006 B2
7138375 Beeley et al. Nov 2006 B2
7138546 Tang Nov 2006 B2
7141240 Perfetti et al. Nov 2006 B2
7141547 Rosen et al. Nov 2006 B2
7144863 Defelippis et al. Dec 2006 B2
7153825 Young et al. Dec 2006 B2
7157555 Beeley et al. Jan 2007 B1
7179788 Defelippis et al. Feb 2007 B2
7189690 Rosen et al. Mar 2007 B2
7220721 Beeley et al. May 2007 B1
7223725 Beeley et al. May 2007 B1
7256253 Bridon et al. Aug 2007 B2
7259136 Hathaway et al. Aug 2007 B2
7259233 Dodd et al. Aug 2007 B2
7259234 Bachovchin et al. Aug 2007 B2
7265087 Göke et al. Sep 2007 B1
7271149 Glaesner et al. Sep 2007 B2
7297761 Beeley et al. Nov 2007 B2
7312196 L'Italien et al. Dec 2007 B2
7329646 Sun et al. Feb 2008 B2
7399489 Kolterman et al. Jul 2008 B2
7399744 Mack et al. Jul 2008 B2
7407932 Young et al. Aug 2008 B2
7407955 Himmelsbach et al. Aug 2008 B2
7414107 Larsen Aug 2008 B2
7419952 Beeley et al. Sep 2008 B2
7442680 Young et al. Oct 2008 B2
7442682 Kitaura et al. Oct 2008 B2
7452858 Hiles et al. Nov 2008 B2
7456254 Wright et al. Nov 2008 B2
7476652 Brunner-Schwarz et al. Jan 2009 B2
7507714 Pan et al. Mar 2009 B2
7521423 Young et al. Apr 2009 B2
7544657 Ebbehøj et al. Jun 2009 B2
7563871 Wright et al. Jul 2009 B2
7576050 Greig et al. Aug 2009 B2
7585837 Shechter et al. Sep 2009 B2
7592010 Rosen et al. Sep 2009 B2
7595293 Engelund et al. Sep 2009 B2
7595294 Nestor Sep 2009 B2
7608692 Prickett et al. Oct 2009 B2
7612176 Wright et al. Nov 2009 B2
7632806 Juul-Mortensen et al. Dec 2009 B2
7638299 Cho et al. Dec 2009 B2
7682356 Alessi et al. Mar 2010 B2
7683030 Prickett et al. Mar 2010 B2
7691963 Prickett et al. Apr 2010 B2
7696161 Beeley et al. Apr 2010 B2
7700549 Beeley et al. Apr 2010 B2
7704953 Herman et al. Apr 2010 B2
7713930 Brunner-Schwarz et al. May 2010 B2
7723471 Levy et al. May 2010 B2
7741269 Young et al. Jun 2010 B2
7749955 Hansen et al. Jul 2010 B2
7772189 Herman et al. Aug 2010 B2
7790681 Hathaway et al. Sep 2010 B2
7799344 Oberg Sep 2010 B2
7799759 Rosen et al. Sep 2010 B2
7803404 Hokenson et al. Sep 2010 B2
7829664 Tatake et al. Nov 2010 B2
7847079 Rosen et al. Dec 2010 B2
7858740 Beeley et al. Dec 2010 B2
7867972 Ballance et al. Jan 2011 B2
7879028 Alessi et al. Feb 2011 B2
7888314 Hathaway et al. Feb 2011 B2
7897560 Dorwald et al. Mar 2011 B2
7906146 Kolterman et al. Mar 2011 B2
7928065 Young et al. Apr 2011 B2
7928186 Chang Apr 2011 B2
7935786 Larsen May 2011 B2
7939494 Khan et al. May 2011 B2
7960341 Hathaway et al. Jun 2011 B2
7977306 Rosen et al. Jul 2011 B2
7981861 Coolidge et al. Jul 2011 B2
7989585 Dodd et al. Aug 2011 B2
7994121 Bachovchin et al. Aug 2011 B2
7994122 Riber et al. Aug 2011 B2
8008255 Ong et al. Aug 2011 B2
8012464 Rosen et al. Sep 2011 B2
8026210 Young et al. Sep 2011 B2
8030273 Au et al. Oct 2011 B2
8039432 Bridon et al. Oct 2011 B2
8057822 Prickett et al. Nov 2011 B2
8071539 Rosen et al. Dec 2011 B2
8076288 Levy et al. Dec 2011 B2
8080516 Bridon et al. Dec 2011 B2
8084414 Bridon et al. Dec 2011 B2
8093206 Bridon et al. Jan 2012 B2
8097239 Johnsson et al. Jan 2012 B2
8097586 Lv et al. Jan 2012 B2
8114632 Melarkode et al. Feb 2012 B2
8114833 Pedersen et al. Feb 2012 B2
8114958 Soares et al. Feb 2012 B2
8114959 Juul-Mortensen Feb 2012 B2
8119648 Himmelsbach et al. Feb 2012 B2
8143217 Balkan et al. Mar 2012 B2
8158579 Ballance et al. Apr 2012 B2
8158583 Knudsen et al. Apr 2012 B2
8178495 Chilkoti May 2012 B2
8178541 Himmelsbach et al. May 2012 B2
8197450 Glejbol et al. Jun 2012 B2
8211439 Rosen et al. Jul 2012 B2
8232281 Dugi et al. Jul 2012 B2
8236760 Pimentel et al. Aug 2012 B2
8252739 Rosen et al. Aug 2012 B2
8263545 Levy et al. Sep 2012 B2
8263550 Beeley et al. Sep 2012 B2
8263554 Tatarkiewicz et al. Sep 2012 B2
8268781 Gotthardt et al. Sep 2012 B2
8278272 Greig et al. Oct 2012 B2
8278420 Wang et al. Oct 2012 B2
8288338 Young et al. Oct 2012 B2
8293726 Habib Oct 2012 B2
8293869 Bossard et al. Oct 2012 B2
8293871 Wright et al. Oct 2012 B2
8299024 Rabinovitch et al. Oct 2012 B2
8299025 Alessi et al. Oct 2012 B2
8329419 Nicolaou et al. Dec 2012 B2
8329648 Fineman et al. Dec 2012 B2
8338368 Dimarchi et al. Dec 2012 B2
8343910 Shechter et al. Jan 2013 B2
8372804 Richardson et al. Feb 2013 B2
8377869 Richardson et al. Feb 2013 B2
8389473 Hathaway et al. Mar 2013 B2
8404637 Levy et al. Mar 2013 B2
8410047 Bock et al. Apr 2013 B2
8420604 Hokenson et al. Apr 2013 B2
8424518 Smutney et al. Apr 2013 B2
8426361 Levy et al. Apr 2013 B2
8431685 Wright et al. Apr 2013 B2
8445647 Prickett et al. May 2013 B2
8450270 Dimarchi et al. May 2013 B2
8454971 Day et al. Jun 2013 B2
8461105 Wright et al. Jun 2013 B2
8481490 Tatarkiewicz et al. Jul 2013 B2
8485180 Smutney et al. Jul 2013 B2
8497240 Levy et al. Jul 2013 B2
8499757 Smutney et al. Aug 2013 B2
8546327 Dimarchi et al. Oct 2013 B2
8551946 Dimarchi et al. Oct 2013 B2
8551947 Coolidge et al. Oct 2013 B2
8557769 Coskun et al. Oct 2013 B2
8557771 Fan et al. Oct 2013 B2
8569481 Köster et al. Oct 2013 B2
8575097 Xu et al. Nov 2013 B2
8580919 Bossard et al. Nov 2013 B2
8598120 Soares et al. Dec 2013 B2
8603761 Nicolaou et al. Dec 2013 B2
8603969 Levy et al. Dec 2013 B2
8614181 Juul-Mortensen et al. Dec 2013 B2
8617613 Wright et al. Dec 2013 B2
8636001 Smutney et al. Jan 2014 B2
8641683 Glejbol et al. Feb 2014 B2
8642544 Alfaro-Lopez et al. Feb 2014 B2
8664232 Himmelsbach et al. Mar 2014 B2
8669228 Dimarchi et al. Mar 2014 B2
8673927 Dugi et al. Mar 2014 B2
8697647 Levy et al. Apr 2014 B2
8697838 Dimarchi et al. Apr 2014 B2
8710002 Rothkopf Apr 2014 B2
8710181 Christiansen et al. Apr 2014 B2
8716221 Lv et al. May 2014 B2
8729018 Chilkoti May 2014 B2
8729019 Oberg et al. May 2014 B2
8735350 Shechter et al. May 2014 B2
8748376 Ludvigsen et al. Jun 2014 B2
8759290 James Jun 2014 B2
8759295 Ghosh et al. Jun 2014 B2
8772232 Lau et al. Jul 2014 B2
8778872 Dimarchi et al. Jul 2014 B2
8785396 Leone-Bay et al. Jul 2014 B2
8801700 Alessi et al. Aug 2014 B2
8809499 Fan et al. Aug 2014 B2
8816047 Levetan et al. Aug 2014 B2
8841255 Chilkoti Sep 2014 B2
8853157 Knudsen et al. Oct 2014 B2
8853160 Greig et al. Oct 2014 B2
8877252 Wright et al. Nov 2014 B2
8877709 Shechter et al. Nov 2014 B2
8883449 Kjeldsen et al. Nov 2014 B2
8889619 Bai et al. Nov 2014 B2
8900593 Day et al. Dec 2014 B2
8969288 Dimarchi et al. Mar 2015 B2
8969294 Bianchi et al. Mar 2015 B2
8980830 Dimarchi et al. Mar 2015 B2
8981047 Dimarchi et al. Mar 2015 B2
9018164 Dimarchi et al. Apr 2015 B2
9181305 Haack et al. Nov 2015 B2
20010011071 Knudsen et al. Aug 2001 A1
20010027180 Isaacs Oct 2001 A1
20010043934 L'Italien et al. Nov 2001 A1
20020061838 Holmquist et al. May 2002 A1
20020137666 Beeley et al. Sep 2002 A1
20020146405 Coolidge et al. Oct 2002 A1
20030036504 Kolterman et al. Feb 2003 A1
20030050237 Kim et al. Mar 2003 A1
20030069182 Rinella et al. Apr 2003 A1
20030087820 Young et al. May 2003 A1
20030087821 Beeley et al. May 2003 A1
20030092606 L'Italien et al. May 2003 A1
20030119021 Koster et al. Jun 2003 A1
20030119734 Flink et al. Jun 2003 A1
20030180287 Gombotz et al. Sep 2003 A1
20030216287 Tang Nov 2003 A1
20030220255 Knudsen et al. Nov 2003 A1
20040023871 Hiles et al. Feb 2004 A1
20040029784 Hathaway Feb 2004 A1
20040037826 Michelsen et al. Feb 2004 A1
20040038865 Gelber et al. Feb 2004 A1
20040048783 Brunner-Schwarz et al. Mar 2004 A1
20040097510 Himmelsbach et al. May 2004 A1
20040209255 Koster et al. Oct 2004 A1
20040209803 Baron et al. Oct 2004 A1
20040242853 Greig et al. Dec 2004 A1
20040266670 Hiles et al. Dec 2004 A9
20040266678 Beeley et al. Dec 2004 A1
20040266683 Hathaway et al. Dec 2004 A1
20040266692 Young et al. Dec 2004 A1
20050009742 Bertilsson et al. Jan 2005 A1
20050009847 Bertilsson et al. Jan 2005 A1
20050009988 Harris et al. Jan 2005 A1
20050043238 Young et al. Feb 2005 A1
20050059601 Beeley et al. Mar 2005 A1
20050096276 Coolidge et al. May 2005 A1
20050101537 Beeley et al. May 2005 A1
20050106214 Chen May 2005 A1
20050143303 Quay et al. Jun 2005 A1
20050171019 Young et al. Aug 2005 A1
20050186174 Bossard Aug 2005 A1
20050197287 Mack et al. Sep 2005 A1
20050209142 Bertilsson et al. Sep 2005 A1
20050215469 Beeley et al. Sep 2005 A1
20050215475 Ong et al. Sep 2005 A1
20050267034 Prickett et al. Dec 2005 A1
20050271702 Wright et al. Dec 2005 A1
20050281879 Chen et al. Dec 2005 A1
20060003918 Kim et al. Jan 2006 A1
20060057137 Steiness Mar 2006 A1
20060069029 Kolterman et al. Mar 2006 A1
20060073182 Wong et al. Apr 2006 A1
20060074012 Hiles et al. Apr 2006 A1
20060079448 Bertilsson et al. Apr 2006 A1
20060084605 Engelund et al. Apr 2006 A1
20060094652 Levy et al. May 2006 A1
20060094653 Levy et al. May 2006 A1
20060110423 Wright et al. May 2006 A1
20060135586 Kozlowski et al. Jun 2006 A1
20060135747 Levy et al. Jun 2006 A1
20060148713 Beeley et al. Jul 2006 A1
20060165733 Betz et al. Jul 2006 A1
20060171920 Shechter et al. Aug 2006 A1
20060172001 Ong et al. Aug 2006 A1
20060178304 Juul-Mortensen et al. Aug 2006 A1
20060183677 Young et al. Aug 2006 A1
20060183682 Juul-Mortensen Aug 2006 A1
20060210614 Quay et al. Sep 2006 A1
20060247167 Schlein et al. Nov 2006 A1
20060275252 Harris et al. Dec 2006 A1
20060287221 Knudsen et al. Dec 2006 A1
20060293232 Levy et al. Dec 2006 A1
20060293499 Bentley et al. Dec 2006 A1
20070010424 Pedersen et al. Jan 2007 A1
20070010656 Beeley et al. Jan 2007 A1
20070014818 Betz et al. Jan 2007 A1
20070021336 Anderson et al. Jan 2007 A1
20070037750 Young et al. Feb 2007 A1
20070049531 Knudsen et al. Mar 2007 A1
20070059373 Oberg Mar 2007 A1
20070059374 Hokenson et al. Mar 2007 A1
20070065469 Betz et al. Mar 2007 A1
20070066528 Beeley et al. Mar 2007 A1
20070092482 Bossard et al. Apr 2007 A1
20070129284 Kjeldsen et al. Jun 2007 A1
20070166352 Wright et al. Jul 2007 A1
20070196416 Li et al. Aug 2007 A1
20070281940 Dugi et al. Dec 2007 A1
20080071063 Allan et al. Mar 2008 A1
20080091176 Alessi et al. Apr 2008 A1
20080119393 Beeley et al. May 2008 A1
20080119569 Wright et al. May 2008 A1
20080125348 Wright et al. May 2008 A1
20080125349 Wright et al. May 2008 A1
20080125351 Wright et al. May 2008 A1
20080125353 Hiles et al. May 2008 A1
20080125361 Ludvigsen et al. May 2008 A1
20080171848 Christiansen et al. Jul 2008 A1
20080176802 Prickett et al. Jul 2008 A1
20080176804 Mack et al. Jul 2008 A1
20080200390 Prickett et al. Aug 2008 A1
20080213288 Michelsen et al. Sep 2008 A1
20080214467 Prickett et al. Sep 2008 A1
20080233053 Gross et al. Sep 2008 A1
20080249007 Lau et al. Oct 2008 A1
20080249018 Kolterman et al. Oct 2008 A1
20080249089 Himmelsbach et al. Oct 2008 A1
20080255159 Himmelsbach et al. Oct 2008 A1
20080260838 Hokenson et al. Oct 2008 A1
20080260847 Wright et al. Oct 2008 A1
20080274952 Soares et al. Nov 2008 A1
20080280814 Ludvigsen et al. Nov 2008 A1
20080300171 Balkan et al. Dec 2008 A1
20080312157 Levy et al. Dec 2008 A1
20080318865 Juul-Mortensen Dec 2008 A1
20090011976 Ludvigsen et al. Jan 2009 A1
20090018053 L'Italien et al. Jan 2009 A1
20090029913 Beeley et al. Jan 2009 A1
20090035253 Wright et al. Feb 2009 A1
20090036364 Levy et al. Feb 2009 A1
20090043264 Glejbol et al. Feb 2009 A1
20090054315 Bock et al. Feb 2009 A1
20090069226 Ong et al. Mar 2009 A1
20090082255 Brunner-Schwarz et al. Mar 2009 A1
20090088369 Steiness Apr 2009 A1
20090098130 Bradshaw et al. Apr 2009 A1
20090110647 Richardson et al. Apr 2009 A1
20090111749 Richardson et al. Apr 2009 A1
20090137456 Dimarchi et al. May 2009 A1
20090137466 Anderson et al. May 2009 A1
20090163423 Young et al. Jun 2009 A1
20090170750 Kjeldsen et al. Jul 2009 A1
20090176704 Beeley et al. Jul 2009 A1
20090180953 Gotthardt et al. Jul 2009 A1
20090186817 Ghosh et al. Jul 2009 A1
20090186819 Carrier et al. Jul 2009 A1
20090203597 Rabinovitch et al. Aug 2009 A1
20090203603 Baron et al. Aug 2009 A1
20090215688 Knudsen et al. Aug 2009 A1
20090215694 Kolterman et al. Aug 2009 A1
20090221485 James Sep 2009 A1
20090226431 Habib Sep 2009 A1
20090232775 Bertilsson et al. Sep 2009 A1
20090232807 Glaesner et al. Sep 2009 A1
20090232891 Gelber et al. Sep 2009 A1
20090239796 Fineman et al. Sep 2009 A1
20090247463 Wright et al. Oct 2009 A1
20090253625 Greig et al. Oct 2009 A1
20090258818 Surolia et al. Oct 2009 A1
20090264352 Anderson et al. Oct 2009 A1
20090280169 Leonard Nov 2009 A1
20090280170 Lee et al. Nov 2009 A1
20090286716 Knudsen et al. Nov 2009 A1
20090286723 Levy et al. Nov 2009 A1
20090291886 Ong et al. Nov 2009 A1
20090298757 Bloom et al. Dec 2009 A1
20090308390 Smutney et al. Dec 2009 A1
20090308391 Smutney et al. Dec 2009 A1
20090308392 Smutney et al. Dec 2009 A1
20090325860 Costantino et al. Dec 2009 A1
20100009904 Lv et al. Jan 2010 A1
20100016806 Glejbol et al. Jan 2010 A1
20100022455 Chilkoti Jan 2010 A1
20100029554 Ghosh et al. Feb 2010 A1
20100041867 Shechter et al. Feb 2010 A1
20100056451 Juul-Mortensen et al. Mar 2010 A1
20100087365 Cherif-Cheikh et al. Apr 2010 A1
20100099619 Levy et al. Apr 2010 A1
20100137558 Lee et al. Jun 2010 A1
20100152097 Wright et al. Jun 2010 A1
20100152111 Wright et al. Jun 2010 A1
20100168011 Jennings, Jr. et al. Jul 2010 A1
20100173844 Ludvigsen et al. Jul 2010 A1
20100185184 Alessi et al. Jul 2010 A1
20100190699 Dimarchi et al. Jul 2010 A1
20100190701 Day et al. Jul 2010 A1
20100190715 Schlein et al. Jul 2010 A1
20100196405 Ng et al. Aug 2010 A1
20100197565 Smutney et al. Aug 2010 A1
20100210505 Bossard et al. Aug 2010 A1
20100216692 Brunner-Schwarz et al. Aug 2010 A1
20100240586 Bao et al. Sep 2010 A1
20100247661 Hokenson et al. Sep 2010 A1
20100261637 Spetzler et al. Oct 2010 A1
20100278924 Oberg et al. Nov 2010 A1
20100292172 Ghosh et al. Nov 2010 A1
20100317056 Tiwari et al. Dec 2010 A1
20100317576 Rothkopf Dec 2010 A1
20100331246 Dimarchi et al. Dec 2010 A1
20110003004 Hokenson et al. Jan 2011 A1
20110034373 Coskun et al. Feb 2011 A1
20110034377 Young et al. Feb 2011 A1
20110059181 Hu et al. Mar 2011 A1
20110065633 Dimarchi et al. Mar 2011 A1
20110065731 Dugi et al. Mar 2011 A1
20110071076 Beeley et al. Mar 2011 A1
20110091420 Liu et al. Apr 2011 A1
20110097386 Steiner et al. Apr 2011 A1
20110097751 Nicolaou et al. Apr 2011 A1
20110098217 Dimarchi et al. Apr 2011 A1
20110112277 Kozlowski et al. May 2011 A1
20110118136 Köster et al. May 2011 A1
20110123487 Chilkoti May 2011 A1
20110129522 Mevorat-Kaplan et al. Jun 2011 A1
20110136737 Levy et al. Jun 2011 A1
20110152181 Alsina-Fernandez et al. Jun 2011 A1
20110152182 Alsina-Fernandez et al. Jun 2011 A1
20110152185 Plum et al. Jun 2011 A1
20110166062 Dimarchi et al. Jul 2011 A1
20110166554 Alessi et al. Jul 2011 A1
20110171178 Levetan et al. Jul 2011 A1
20110178014 Hathaway et al. Jul 2011 A1
20110178242 Harris et al. Jul 2011 A1
20110190200 Dimarchi et al. Aug 2011 A1
20110195897 Kajihara et al. Aug 2011 A1
20110230409 Knudsen et al. Sep 2011 A1
20110237503 Alsina-Fernandez et al. Sep 2011 A1
20110237510 Steiner et al. Sep 2011 A1
20110245162 Fineman et al. Oct 2011 A1
20110257092 Dimarchi et al. Oct 2011 A1
20110263496 Fineman et al. Oct 2011 A1
20110281798 Kolterman et al. Nov 2011 A1
20110288003 Dimarchi et al. Nov 2011 A1
20110301080 Bush et al. Dec 2011 A1
20110301081 Becker et al. Dec 2011 A1
20110301084 Lau et al. Dec 2011 A1
20110306549 Tatarkiewicz et al. Dec 2011 A1
20120004168 Young et al. Jan 2012 A1
20120021978 Werner et al. Jan 2012 A1
20120040899 Costello et al. Feb 2012 A1
20120046222 Alfaro-Lopez et al. Feb 2012 A1
20120071510 Leone-Bay et al. Mar 2012 A1
20120071817 Ward et al. Mar 2012 A1
20120094356 Chung et al. Apr 2012 A1
20120100070 Ahn et al. Apr 2012 A1
20120122783 Dimarchi et al. May 2012 A1
20120135922 Prickett et al. May 2012 A1
20120136318 Lanin et al. May 2012 A1
20120148586 Chou et al. Jun 2012 A1
20120149639 Balkan et al. Jun 2012 A1
20120157932 Glejbol et al. Jun 2012 A1
20120172295 Dimarchi et al. Jul 2012 A1
20120177697 Chen Jul 2012 A1
20120196795 Xu et al. Aug 2012 A1
20120196796 Soares et al. Aug 2012 A1
20120196802 Lv et al. Aug 2012 A1
20120196804 Dimarchi et al. Aug 2012 A1
20120208755 Leung et al. Aug 2012 A1
20120208831 Himmelsbach et al. Aug 2012 A1
20120209213 Theucher Aug 2012 A1
20120225810 Pedersen et al. Sep 2012 A1
20120231022 Bass et al. Sep 2012 A1
20120238493 Dimarchi et al. Sep 2012 A1
20120238496 Fan et al. Sep 2012 A1
20120253023 Levy et al. Oct 2012 A1
20120258912 Bentley et al. Oct 2012 A1
20120258985 Kozlowski et al. Oct 2012 A1
20120264683 Coskun et al. Oct 2012 A1
20120264684 Kajihara et al. Oct 2012 A1
20120276098 Hamilton et al. Nov 2012 A1
20120277154 Fan et al. Nov 2012 A1
20120283179 Brunner-Schwarz et al. Nov 2012 A1
20120294855 Van Cauter et al. Nov 2012 A1
20120295836 Knudsen et al. Nov 2012 A1
20120295846 Hagendorf et al. Nov 2012 A1
20120295850 Tatarkiewicz et al. Nov 2012 A1
20120302501 Coolidge et al. Nov 2012 A1
20120309975 Colca et al. Dec 2012 A1
20120316108 Chen et al. Dec 2012 A1
20120316138 Colca et al. Dec 2012 A1
20120322725 Dimarchi et al. Dec 2012 A1
20120322728 Colca et al. Dec 2012 A1
20120329715 Greig et al. Dec 2012 A1
20130005664 Chilkoti Jan 2013 A1
20130023470 Young et al. Jan 2013 A1
20130023471 Rabinovitch et al. Jan 2013 A1
20130310538 Chilkoti Jan 2013 A1
20130046245 Raab et al. Feb 2013 A1
20130053350 Colca et al. Feb 2013 A1
20130065826 Soula et al. Mar 2013 A1
20130079277 Chilkoti Mar 2013 A1
20130079278 Lau et al. Mar 2013 A1
20130084277 Arnold et al. Apr 2013 A1
20130085099 Chilkoti Apr 2013 A1
20130085104 Chilkoti Apr 2013 A1
20130089878 Nicolaou et al. Apr 2013 A1
20130090286 Bianchi et al. Apr 2013 A1
20130095037 Gotthardt et al. Apr 2013 A1
20130096258 Bossard et al. Apr 2013 A1
20130104887 Smutney et al. May 2013 A1
20130116172 Dimarchi et al. May 2013 A1
20130116175 Shechter et al. May 2013 A1
20130118491 Richardson et al. May 2013 A1
20130123178 Dimarchi et al. May 2013 A1
20130123462 Dimarchi et al. May 2013 A1
20130125886 Richardson et al. May 2013 A1
20130130977 Wright et al. May 2013 A1
20130137631 Levy et al. May 2013 A1
20130137645 Rosendahl May 2013 A1
20130142795 Bai et al. Jun 2013 A1
20130156849 De Fougerolles et al. Jun 2013 A1
20130157934 Dimarchi et al. Jun 2013 A1
20130157953 Petersen et al. Jun 2013 A1
20130164310 Annathur et al. Jun 2013 A1
20130165370 Bock et al. Jun 2013 A1
20130165379 Kolterman et al. Jun 2013 A1
20130172274 Chilkoti Jul 2013 A1
20130178411 Chilkoti Jul 2013 A1
20130178415 Soula et al. Jul 2013 A1
20130184203 Alfaro-Lopez et al. Jul 2013 A1
20130184443 Bentley et al. Jul 2013 A1
20130189365 Hokenson et al. Jul 2013 A1
20130199527 Smutney et al. Aug 2013 A1
20130203660 Day et al. Aug 2013 A1
20130209586 Hathaway et al. Aug 2013 A1
20130217622 Lee et al. Aug 2013 A1
20130236974 De Fougerolles Sep 2013 A1
20130237592 De Fougerolles et al. Sep 2013 A1
20130237593 De Fougerolles et al. Sep 2013 A1
20130237594 De Fougerolles et al. Sep 2013 A1
20130244278 De Fougerolles et al. Sep 2013 A1
20130244279 De Fougerolles et al. Sep 2013 A1
20130245104 De Fougerolles et al. Sep 2013 A1
20130245105 De Fougerolles et al. Sep 2013 A1
20130245106 De Fougerolles et al. Sep 2013 A1
20130245107 De Fougerolles et al. Sep 2013 A1
20130252281 De Fougerolles et al. Sep 2013 A1
20130253043 De Fougerolles et al. Sep 2013 A1
20130259923 Bancel et al. Oct 2013 A1
20130259924 Bancel et al. Oct 2013 A1
20130266640 De Fougerolles et al. Oct 2013 A1
20130280206 Kozlowski et al. Oct 2013 A1
20130281368 Bilsky et al. Oct 2013 A1
20130281374 Levy et al. Oct 2013 A1
20130284912 Vogel et al. Oct 2013 A1
20130288958 Lau et al. Oct 2013 A1
20130289241 Bai et al. Oct 2013 A1
20130291866 Smutney et al. Nov 2013 A1
20130291867 Smutney et al. Nov 2013 A1
20130296236 Silvestre et al. Nov 2013 A1
20130303442 Levy et al. Nov 2013 A1
20130310310 Liu et al. Nov 2013 A1
20130331322 Young et al. Dec 2013 A1
20130336893 Haack et al. Dec 2013 A1
20130338065 Smutney et al. Dec 2013 A1
20130338071 Knudsen et al. Dec 2013 A1
20130345134 Sauerberg et al. Dec 2013 A1
20140007873 Smutney et al. Jan 2014 A1
20140011732 Spetzler et al. Jan 2014 A1
20140014106 Smutney et al. Jan 2014 A1
20140017208 Osei Jan 2014 A1
20140031281 Wright et al. Jan 2014 A1
20140038891 Prickett et al. Feb 2014 A1
20140056924 Van Cauter Feb 2014 A1
20140066368 Mack et al. Mar 2014 A1
20140083421 Smutney et al. Mar 2014 A1
20140088003 Wright et al. Mar 2014 A1
20140100156 Haack et al. Apr 2014 A1
20140107019 Erickson et al. Apr 2014 A1
20140107021 Dimarchi et al. Apr 2014 A1
20140120120 Woo et al. May 2014 A1
20140121352 Shechter et al. May 2014 A1
20140128318 Jung et al. May 2014 A1
20140128604 Himmelsbach et al. May 2014 A1
20140135348 Dugi et al. May 2014 A1
20140141467 Tiwari et al. May 2014 A1
20140142037 Yue May 2014 A1
20140162943 Alfaro-Lopez et al. Jun 2014 A1
20140187483 Steiness Jul 2014 A1
20140200183 Hathaway et al. Jul 2014 A1
20140206608 Haack et al. Jul 2014 A1
20140206609 Haack et al. Jul 2014 A1
20140206613 Rabinovitch et al. Jul 2014 A1
20140206615 Knudsen et al. Jul 2014 A1
20140212419 Dimarchi et al. Jul 2014 A1
20140212440 Jung et al. Jul 2014 A1
20140213513 Haack et al. Jul 2014 A1
20140213516 Chilkoti Jul 2014 A1
20140220029 Michelsen et al. Aug 2014 A1
20140220134 Zierhut et al. Aug 2014 A1
20140221280 Bloom Aug 2014 A1
20140221281 Haack et al. Aug 2014 A1
20140221282 Sun et al. Aug 2014 A1
20140227264 Hamilton et al. Aug 2014 A1
20140235535 Erickson et al. Aug 2014 A1
20140243263 Rothkopf Aug 2014 A1
20140249299 Levy et al. Sep 2014 A1
20140308358 Oberg et al. Oct 2014 A1
20140309168 Rosendahl Oct 2014 A1
20140315953 Leone-Bay et al. Oct 2014 A1
20150011467 Bloom et al. Jan 2015 A1
20150126440 Day et al. May 2015 A1
20150164995 Kadereit et al. Jun 2015 A1
20150164996 Kadereit et al. Jun 2015 A1
20150164997 Haack et al. Jun 2015 A1
20150166625 Haack et al. Jun 2015 A1
20150166627 Kadereit et al. Jun 2015 A1
20150216941 Bley et al. Aug 2015 A1
20150232527 Gong et al. Aug 2015 A1
20150315260 Bossart et al. Nov 2015 A1
20150322128 Bossart et al. Nov 2015 A1
20150322129 Bossart et al. Nov 2015 A1
20150368311 Haack et al. Dec 2015 A1
20160168225 Haack et al. Jun 2016 A1
20160235855 Xiong et al. Aug 2016 A1
Foreign Referenced Citations (331)
Number Date Country
101538323 Sep 2009 CN
101559041 Oct 2009 CN
101663317 Mar 2010 CN
101798588 Aug 2010 CN
101870728 Oct 2010 CN
101601646 Mar 2011 CN
102100906 Jun 2011 CN
102363633 Feb 2012 CN
102421796 Apr 2012 CN
101444618 Jun 2012 CN
102532301 Jul 2012 CN
102649947 Aug 2012 CN
102816244 Dec 2012 CN
102827270 Dec 2012 CN
101670096 Jan 2013 CN
103304660 Sep 2013 CN
103421094 Dec 2013 CN
103665148 Mar 2014 CN
103833841 Jun 2014 CN
103908657 Jul 2014 CN
102766204 Oct 2014 CN
104926934 Sep 2015 CN
1 140 145 Jul 2005 EP
0 619 322 Dec 2005 EP
1 609 478 Dec 2005 EP
1 143 989 Dec 2006 EP
1 658 856 Mar 2010 EP
1 684 793 Sep 2011 EP
1 633 391 Oct 2011 EP
2387989 Nov 2011 EP
1 633 390 Jan 2012 EP
2 494 983 Sep 2012 EP
2 626 368 Aug 2013 EP
2 664 374 Nov 2013 EP
1 817 048 Feb 2014 EP
2 769 990 Aug 2014 EP
2014-227368 Dec 2014 JP
10-2012-0137271 Dec 2012 KR
10-2012-0139579 Dec 2012 KR
10-2014-0018462 Feb 2014 KR
10-2014-0058104 May 2014 KR
10-2014-0058387 May 2014 KR
10-2014-0130659 Nov 2014 KR
10-2014-0133493 Nov 2014 KR
2009121626 Feb 2011 RU
9619229 Jun 1996 WO
9805351 Feb 1998 WO
9808871 Mar 1998 WO
9830231 Jul 1998 WO
9907404 Feb 1999 WO
9925727 May 1999 WO
9925728 May 1999 WO
9934822 Jul 1999 WO
9943708 Sep 1999 WO
9947160 Sep 1999 WO
9964061 Dec 1999 WO
0015224 Mar 2000 WO
0037098 Jun 2000 WO
0041546 Jul 2000 WO
0041548 Jul 2000 WO
0055119 Sep 2000 WO
0066629 Nov 2000 WO
0071175 Nov 2000 WO
0073331 Dec 2000 WO
0151078 Jul 2001 WO
0216309 Feb 2002 WO
0234285 May 2002 WO
02067989 Sep 2002 WO
03011892 Feb 2003 WO
03020201 Mar 2003 WO
03061362 Jul 2003 WO
03077851 Sep 2003 WO
03084563 Oct 2003 WO
03092581 Nov 2003 WO
03099314 Dec 2003 WO
03101395 Dec 2003 WO
03105888 Dec 2003 WO
03105897 Dec 2003 WO
2004004779 Jan 2004 WO
2004004780 Jan 2004 WO
2004004781 Jan 2004 WO
2004005342 Jan 2004 WO
2004012672 Feb 2004 WO
2004018468 Mar 2004 WO
2004035623 Apr 2004 WO
2004045592 Jun 2004 WO
2004056313 Jul 2004 WO
2004056317 Jul 2004 WO
2004089280 Oct 2004 WO
2004089985 Oct 2004 WO
2004105781 Dec 2004 WO
2004105790 Dec 2004 WO
2005000222 Jan 2005 WO
2005000360 Jan 2005 WO
2005012347 Feb 2005 WO
2005021022 Mar 2005 WO
2005046716 May 2005 WO
2005048989 Jun 2005 WO
2005049061 Jun 2005 WO
2005049069 Jun 2005 WO
2005054291 Jun 2005 WO
2005077072 Aug 2005 WO
2005077094 Aug 2005 WO
2005081619 Sep 2005 WO
2005102293 Nov 2005 WO
2005110425 Nov 2005 WO
2005115437 Dec 2005 WO
2005117584 Dec 2005 WO
2005120492 Dec 2005 WO
2006017688 Feb 2006 WO
2006024275 Mar 2006 WO
2006024631 Mar 2006 WO
2006029634 Mar 2006 WO
2006037811 Apr 2006 WO
2006044531 Apr 2006 WO
2006051103 May 2006 WO
2006051110 May 2006 WO
2006066024 Jun 2006 WO
2006069388 Jun 2006 WO
2006073890 Jul 2006 WO
2006074600 Jul 2006 WO
2006083254 Aug 2006 WO
2006086769 Aug 2006 WO
2006097535 Sep 2006 WO
2006110887 Oct 2006 WO
2006114396 Nov 2006 WO
2006125763 Nov 2006 WO
2006138572 Dec 2006 WO
2006134340 Dec 2006 WO
2007019331 Feb 2007 WO
2007022123 Mar 2007 WO
2007024700 Mar 2007 WO
2007033316 Mar 2007 WO
2007033372 Mar 2007 WO
2007035665 Mar 2007 WO
2007047834 Apr 2007 WO
2007047922 Apr 2007 WO
2007056362 May 2007 WO
2007064691 Jun 2007 WO
2007065156 Jun 2007 WO
2007067964 Jun 2007 WO
2007075534 Jul 2007 WO
2007109354 Sep 2007 WO
2007120899 Oct 2007 WO
2007121411 Oct 2007 WO
2007128761 Nov 2007 WO
2007133778 Nov 2007 WO
2007139941 Dec 2007 WO
2007140284 Dec 2007 WO
2008021133 Feb 2008 WO
2008021560 Feb 2008 WO
2008023050 Feb 2008 WO
2008038147 Apr 2008 WO
2008058461 May 2008 WO
2008073448 Jun 2008 WO
2008071972 Jun 2008 WO
2008081418 Jul 2008 WO
2008086086 Jul 2008 WO
2008098212 Aug 2008 WO
2008101017 Aug 2008 WO
2008148839 Dec 2008 WO
2008152403 Dec 2008 WO
2009020802 Feb 2009 WO
2009024015 Feb 2009 WO
2009029847 Mar 2009 WO
2009030771 Mar 2009 WO
2009035540 Mar 2009 WO
2009055740 Apr 2009 WO
2009055742 Apr 2009 WO
2009058662 May 2009 WO
2009058734 May 2009 WO
2009063072 May 2009 WO
2009067268 May 2009 WO
2009095479 Aug 2009 WO
2009099763 Aug 2009 WO
2009113099 Sep 2009 WO
2009137078 Nov 2009 WO
2009137080 Nov 2009 WO
2009143014 Nov 2009 WO
2009143285 Nov 2009 WO
2009152477 Dec 2009 WO
2009153960 Dec 2009 WO
2009155257 Dec 2009 WO
2009158704 Dec 2009 WO
2009155258 Dec 2009 WO
2010011439 Jan 2010 WO
2010013012 Feb 2010 WO
2010043566 Apr 2010 WO
2010071807 Jun 2010 WO
2010070251 Jun 2010 WO
2010070252 Jun 2010 WO
2010070253 Jun 2010 WO
2010070255 Jun 2010 WO
2010096052 Aug 2010 WO
2010096142 Aug 2010 WO
2010102148 Sep 2010 WO
2010120476 Oct 2010 WO
2010121559 Oct 2010 WO
2010123290 Oct 2010 WO
2010133675 Nov 2010 WO
2010133676 Nov 2010 WO
2010138671 Dec 2010 WO
2010142665 Dec 2010 WO
2010148089 Dec 2010 WO
2011000095 Jan 2011 WO
2011006497 Jan 2011 WO
2011011675 Jan 2011 WO
2011000497 Jan 2011 WO
2011012718 Feb 2011 WO
2011020319 Feb 2011 WO
2011020320 Feb 2011 WO
2011024110 Mar 2011 WO
2011039096 Apr 2011 WO
2011049713 Apr 2011 WO
2011052523 May 2011 WO
2011056713 May 2011 WO
2011058082 May 2011 WO
2011058083 May 2011 WO
2011075514 Jun 2011 WO
2011075623 Jun 2011 WO
2011075393 Jun 2011 WO
2011080103 Jul 2011 WO
2011084453 Jul 2011 WO
2011084456 Jul 2011 WO
2011084459 Jul 2011 WO
2011087671 Jul 2011 WO
2011087672 Jul 2011 WO
2011088837 Jul 2011 WO
2011094337 Aug 2011 WO
2011109784 Sep 2011 WO
2011119657 Sep 2011 WO
2011117415 Sep 2011 WO
2011117416 Sep 2011 WO
2011143208 Nov 2011 WO
2011143209 Nov 2011 WO
2011144751 Nov 2011 WO
2011153965 Dec 2011 WO
2011156407 Dec 2011 WO
2011162830 Dec 2011 WO
2011163012 Dec 2011 WO
2011163272 Dec 2011 WO
2011163473 Dec 2011 WO
2011160630 Dec 2011 WO
2012012352 Jan 2012 WO
2012012460 Jan 2012 WO
2012015975 Feb 2012 WO
2012031518 Mar 2012 WO
2012035139 Mar 2012 WO
2012050923 Apr 2012 WO
2012059762 May 2012 WO
2012064892 May 2012 WO
2012080471 Jun 2012 WO
2012088157 Jun 2012 WO
2012088116 Jun 2012 WO
2012122535 Sep 2012 WO
2012130015 Oct 2012 WO
2012138941 Oct 2012 WO
2012140647 Oct 2012 WO
2012150503 Nov 2012 WO
2012158965 Nov 2012 WO
2012162547 Nov 2012 WO
2012167744 Dec 2012 WO
2012169798 Dec 2012 WO
2012173422 Dec 2012 WO
2012177443 Dec 2012 WO
2012177444 Dec 2012 WO
2012177929 Dec 2012 WO
2013002580 Jan 2013 WO
2013004983 Jan 2013 WO
2013009545 Jan 2013 WO
2013029279 Mar 2013 WO
2013041678 Mar 2013 WO
2012174478 May 2013 WO
2013060850 May 2013 WO
2013074910 May 2013 WO
2013078500 Jun 2013 WO
2013090648 Jun 2013 WO
2013092703 Jun 2013 WO
2013093720 Jun 2013 WO
2013101749 Jul 2013 WO
2013104861 Jul 2013 WO
2013148871 Oct 2013 WO
2013148966 Oct 2013 WO
2013151663 Oct 2013 WO
2013151664 Oct 2013 WO
2013151665 Oct 2013 WO
2013151666 Oct 2013 WO
2013151667 Oct 2013 WO
2013151668 Oct 2013 WO
2013151669 Oct 2013 WO
2013151670 Oct 2013 WO
2013151671 Oct 2013 WO
2013151672 Oct 2013 WO
2013151736 Oct 2013 WO
2013160397 Oct 2013 WO
2013163162 Oct 2013 WO
2013164484 Nov 2013 WO
2013171135 Nov 2013 WO
2013177565 Nov 2013 WO
2013186240 Dec 2013 WO
2013192130 Dec 2013 WO
2014012069 Jan 2014 WO
2014016300 Jan 2014 WO
2014017843 Jan 2014 WO
2014017845 Jan 2014 WO
2014017849 Jan 2014 WO
2014027253 Feb 2014 WO
2014027254 Feb 2014 WO
2014041195 Mar 2014 WO
2014041375 Mar 2014 WO
2014056872 Apr 2014 WO
2014073842 May 2014 WO
2014073845 May 2014 WO
2014081872 May 2014 WO
2014091316 Jun 2014 WO
2014096145 Jun 2014 WO
2014140222 Sep 2014 WO
2014152460 Sep 2014 WO
2014158900 Oct 2014 WO
2014170496 Oct 2014 WO
2015055801 Apr 2015 WO
2015055802 Apr 2015 WO
2015067716 May 2015 WO
2015086728 Jun 2015 WO
2015086729 Jun 2015 WO
2015086730 Jun 2015 WO
2015086731 Jun 2015 WO
2015086732 Jun 2015 WO
2015086733 Jun 2015 WO
2015100876 Jul 2015 WO
2015104314 Jul 2015 WO
Non-Patent Literature Citations (185)
Entry
US 8,729,011, 05/2014, Dimarchi et al. (withdrawn)
Day, Jonathan W., et al. “A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.” Nature chemical biology 5.10 (2009): 749-757.
Eng, John, et al. “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.” Journal of Biological Chemistry 267.11 (1992): 7402-7405.
Extended European Search Report for Application No. EP 13306717, dated Jun. 3, 2014 (11 pages).
Bhat, Vikas K., et al. “A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.” Biochemical pharmacology 85.11 (2013): 1655-1662.
Bhat, V. K., et al. “A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.” Diabetologia 56.6 (2013): 1417-1424.
Gentilella, R., et al. “Exenatide: a review from pharmacology to clinical practice.” Diabetes, Obesity and Metabolism 11.6 (2009): 544-556.
Hjorth, Siv A., et al. “Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes.” Journal of Biological Chemistry269.48 (1994): 30121-30124.
Pedersen, Jesper Sondergaard, Dancho Dikov, and Daniel Erik Otzen. “N-and C-terminal hydrophobic patches are involved in fibrillation of glucagon.”Biochemistry 45.48 (2006): 14503-14512.
Yun, Ji-Hye, et al. “Solution Structure of LXXLL-related Cofactor Peptide of Orphan Nuclear Receptor FTZ-F1.” Bulletin of the Korean Chemical Society 33.2 (2012): 583-588.
Krstenansky, John L., Dev Trivedi, and Victor J. Hruby. “Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase.” Biochemistry 25.13 (1986): 3833-3839.
Pocai, Alessandro, et al. “Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.” Diabetes 58.10 (2009): 2258-2266.
Kosinski, Jennifer R., et al. “The Glucagon Receptor Is Involved in Mediating the Body Weight—Lowering Effects of Oxyntomodulin.” Obesity 20.8 (2012): 1566-1571.
Shiau, Andrew K., et al. “The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.” Cell 95.7 (1998): 927-937.
Korczyn, A.D. and Nussbaum, M., “Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease,” Drugs 62:775-786 (2002).
Margolis , R. “Diagnosis of Huntington's Disease,”Clin. Chem. 49:1726-32 (2003).
Martin, et al. “Neurodegenation in excitotoxcity, global cerebral ischemia, and target deprivation: A perspective on the contributions of aptopsis and necrosis,” Brain Res. Bull, 46:281-309 (1998).
Medline Plus, obesity, available at http://www.nlm.nih.gov/medlineplus/obesity.html—(referenced Aug. 22, 2013).
St. John Providence Health Center; Preventing Obesity; http://www.stjohnprovidence.org/HealthInfoLib/swarticle.aspx?type=85&id=P07863 (referenced Aug. 22, 2013).
EMedicine Health, diabetes causes, http://www.onhealth.com/diabetes—health/page3.htm#diabetes—causes (referenced Aug. 22, 2013).
United Healthcare, diabetes, http://www.uhc.com/source4women/health—topics/diabetes/relatedinformation/d0f0417b073bf110VgnVCM1000002f10b10a—.htm-referenced Aug. 22, 2013.
WHO Cardiovascular guidelines “Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk” accessed at Mar. 16, 2015 at URL who.intJcardiovascular—diseases/guidelines/Full%20text.pdf.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2015/063607, mailed Sep. 23, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2016/062496, mailed Aug. 3, 2016.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2016/063332, mailed Aug. 10, 2016.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2016/063339, mailed Aug. 8, 2016.
Amylin Pharmaceuticals, Inc. (2007) “Byetta: Exenatide Injection,” Product Information. Accessible on the Internet at URL: http://www.accessdata.fda.gov/drugsatfda—docs/label/2008/021773s012lbl.pdf. [Last Accessed Jun. 2, 2014].
Baggio et al. (2007) “Biology of incretins: GLP-1 and GIP,” Gastroenterology. 132:2131-2157.
Biron et al. (2006) “Optimized selective N-methylation of peptides on solid support,” J. Peptide Sci. 12:213-219.
Bis et al. (Jun. 27, 2014) “Antimicrobial preservatives induce aggregation of interferon alpha-2a: the order in which preservatives induce protein aggregation is independent of the protein,” Int. J. Pharm. 472:356-361.
Braga et al. (2005) “Making Crystals from Crystals: a green route to crystal engineering and polymorphism,” Chem. Commun. 2005:3635-3645.
Bromer (1983) “Chemical Characteristics of Glucagon,” Handbook of Experimental Pharmacology. 66:1-22.
Bunck et al. (Sep. 2011) “Effects of Exenatide on Measures of B-Cell Function After 3 Years in Metformin-Treated Patients with Type 2 Diabetes,” Diabetes Care. 34:2041-2047.
Buse et al. (2009) “Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel group, multinational, open-label trial (LEAD-6),” The Lacenet. 374:39-47.
Chae et al. (2010) “The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics,” Journal of Controlled Release. 144:10-16.
Chen et al. (Jan. 2014) “Hyaluronic acid-based drug conjugates: state-of-the-art and perspectives,” J. Biomed. Nanotechnol. 10(1):4-16.
Chhabra et al. (1998) “An Appraisal of New Variants of Dde Amine Protecting Group for Solid Phase Peptide Synthesis,” Tetrahedron Letters. 39:1603-1606.
Creutzfeld et al. (1978) “Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels,” Diabetologia. 14:15-24.
Deacon (2004) “Circulation and degradation of GIP and GLP-1,” Horm. Metab. Res. 36:761-765.
Donnelly (May 2012) “The structure and function of the glucagon-like peptide-1 receptor and its ligands,” Br. J. Pharmacol. 166(1 ):27-41.
Druce et al. (2009) “Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs,” Endocrinology. 150(4):1712-1722.
Drucker et al. (2010) “Liraglutide,” New Reviews—Drug Discovery. 9(4):267-268.
Eng et al. (1990) “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem. 265:20259-20262.
Eng et al. (1996) “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db Mice,” Diabetes. 45:152A. Abstract 554.
Ficht et al. (2008) “Solid-phase Synthesis of Peptide and Glycopeptide Thioesters through Side-Chain-Anchoring Strategies,” Chem. Eur. J. 14:3620-3629.
Finan et al. (Dec. 8, 2014) “A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents,” Nat. Med. 21(1):27-36.—with supplementary information.
Finan et al. (Oct. 30, 2013) “Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans,” Sci. Trans. Med. 5:209RA151.
Furman (Mar. 15, 2012) “The development of Byetta (exenatide) from the venom of the Gilo monster as an anti-liabetic agent,” Toxicon. 59:464-471.
Gault et al. (2007) “Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets,” Diabetologia. 50:1752-1762.
Gault et al. (Aug. 1, 2011) “Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity,” Clin Sci (Lond). 121:107-117.
Göke et al. (1993) “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem. 268:19650-19655.
Hadji-Georgopoulos et al. (1983) “Increased gastric inhibitory polypeptide levels in patients with symptomatic postprandial hypoglycemia,” J. Endocrinol. Metabol. 56(4):648-652.
Hargrove et al. (2007) “Biological Activity of AC3174, A Peptide Analog of Exendin-4,” Regulatory Peptides. 141:113-119.
Heppner et al. (2010) “Glucagon regulation of energy metabolism,” Physiol. Behav. 100:545-548.
Herling et al. (1998) “Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system,” Am. J. Physiol. 274(6 Pt 1):G1087-G1093.
Holst (2007) “The physiology of glucagon-like peptide 1,” Physiol. Rev. 87(4):1409-1439.
Joshi et al. (2000) “The degradation pathways of glucagon in acidic solutions,” Int. J. Pharm. 203(1-2):115-125.
Kaiser et al. (1970) “Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides.” Anal. Biochem. 34:595-598.
Kamerzell et al. (2011) “Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development,” Adv. Drug Deliv. Rev. 63:1118-1159.
Kazakos et al. (2011) “Incretin effect: GLP-1, GIP, DPP4,” Diabetes Res Clin Pract. 93(Suppl 1):S32-S36. et al. (2011) “Incretin effect: GLP-1, GIP, DPP4,” Diabetes Res Clin Pract. 93(Suppl 1):S32-S36.
King et al. (1990) “A Cleavage Method which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis,” International Journal of Peptide Protein Research. 36:255-266.
Knudsen et al. (2000) “Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration” J. Med. Chem. 43(9):1664-1669.
Kong et al. (2010) “Long acting hyaluronate-exendin 4 conjugate for the treatment of type 2 diabetes,” Biomaterials. 31:4121-4128.
Lee et al. (May 10, 2013) “Hormonal Response to a Mixed-Meal Challenge After Reversal of Gastric Bypass for Hypoglycemia,” J. Clin. Endocrinol. Metab. 98(7):E1208-E1212.
Li et al.(Jul. 25, 2012) “Cloning, expressing of Exendin-4 analogue and bioactivity analysis in vivo,” Chinese Journal of Biotechnology. 28(7):877-886.
Liu et al. (2011) “Solid phase peptide synthesis and analysis for exendin-4,” China Biotechnology. 31(2):69-73.—English abstract and drawings.
Lorenz et al. (2013) “Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity” Bioorg. Med. Chem. Lett. 23(14):4011-4018.
Lozano et al. (2013) “Polyarginine nanocapsules: a new platform for intracellular drug delivery,” Journal of Nanoparticle Research. 15:1515. pp. 1-14.
McLaughlin et al. (2010) “Reversible Hyperinsulinemic Hypoglycemia after Gastric Bypass: A Consequence of Altered Nutrient Delivery,” J. Clin. Endocrinol. Metabol. 95(4):1851-1855.
Meier (Sep. 4, 2012) “GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus,” Nat. Rev. Endocrinol. 8:728-742.
Meier et al. (May 21, 2015) “Incretin-based therapies: where will we be 50 years from now?” Diabetologia. 58:1745-1750.
Miyawaki et al. (2002) “Inhibition of gastric inhibitory polypeptide signaling prevents obesity,” Nat. Med. 8(7):738-742.
Murage et al. (2008) “Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1,” Bioorg. Med. Chem. 16:10106-10112.
Nauck et al. (1993) “Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations,” J. Clin. Endocrinol. Metab. 76:912-917.
Norris et al. (2009) “Exenatide Efficacy and Safety: A Systematic Review,” Diabetic Medicine. 26:837-846.
Norwegian Institute of Public Health (Dec. 19, 2013) ATC/DDD Index for Cardiovascular System.
Oh et al. (2010) “Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using iyaluronic acid derivatives,” Journal of Controlled Release. 141:2-12.
Pan et al. (2006) “Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist.” Journal of Biological Chemistry. 281(18):12506-12515.
Pocai (Dec. 14, 2013) “Action and therapeutic potential of oxyntomodulin,” Molecular Metabolism 3:2412-51.
Rentier et al. (Mar. 26, 2015) “Synthesis of diastereomerically pure Lys(Nε-lipoyl) building blocks and their use in Fmoc/tBu solid phase synthesis of lipoyl-containing peptides for diagnosis of primary biliary cirrhosis,” Journal of Peptide Science. 21(5):408-414.
Robberecht et al. (1986) “Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat,” Peptides. 7(1):109-112.
Rovo et al. (May 2014) “Rational design of a-helix-stabilized exendin-4 analogues,” Biochemistry. 53(22):3540-3552.
Seddon (2004) “Pseudopolymorph: A polemic,” Crystal Growth and Design. 4(6):1087.
Tasyurek et al. (Jul. 2014) “Incretins: Their physiology and application in the treatment of diabetes mellitus,” Diabetes Metab. Res. Rev. 30(5):354-371.
Ueda et al. (2010) “Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution,” Bioorg. Med. Chem. Lett. 20(15):4631-4634.
Unison et al. (1993) “The role of histidine-1 in glucagon action,” Arch. Biochem. Biophys. 300(2):747-750.
Vippagunta et al. (2001) “Crystalline Solids,” Advanced Drug Delivery Reviews. 48:3-26.
Vojkovsky (1995) “Detection of secondary amines on solid phase,” Peptide Research 8:236-237.
Ward et al. (Nov. 2013) “Peptide lipidation stabilizes structure to enhance biological function,” Mol. Metabol. 2 (4):468-479.
European Search Report corresponding to European Patent Application No. 12172010, dated Apr. 19, 2013.
European Search Report corresponding to European Patent Application No. 12306232, dated Apr. 19, 2013.
European Search Report corresponding to European Patent Application No. 12306647, dated May 22, 2013.
European Search Report corresponding to European Patent Application No. 13306712, dated May 27, 2014.
European Search Report corresponding to European Patent Application No. 13306713, dated Jun. 12, 2014.
European Search Report corresponding to European Patent Application No. 13306714, dated May 28, 2014.
European Search Report corresponding to European Patent Application No. 13306715, dated Jun. 12, 2014.
European Search Report corresponding to European Patent Application No. 13306716, dated May 27, 2014.
European Search Report corresponding to European Patent Application No. 13505222, dated Jul. 15, 2013.
European Search Report corresponding to European Patent Application No. 14305503, dated Sep. 23, 2014.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/062090, issued Nov. 24, 2014.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/070882, issued Dec. 1, 2014.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/077307, issued Feb. 12, 2015.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/077310, issued Feb. 2, 2015.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/077312, issued Feb. 13, 2015.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/077313, issued Feb. 12, 2015.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2014/077336, dated Feb. 26, 2016.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2014/077337, dated Jun. 14, 2016.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2014/077338, dated Jun. 14, 2016.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2014/077339, dated Jun. 14, 2016.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2014/077340, dated Jun. 14, 2016.
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2014/077341, dated Jun. 14, 2016.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/062090, mailed Feb. 7, 2014.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/070882, mailed Dec. 5, 2013.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/077307, mailed Feb. 18, 2014.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/077310, mailed Feb. 18, 2014.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/077312, mailed Feb. 18, 2014.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/077313, mailed Feb. 18, 2014.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/077336, mailed Mar. 18, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/077337, mailed Apr. 1, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/077338, mailed Mar. 26, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/077339, mailed May 11, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/077340, mailed Mar. 18, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/077341, mailed Mar. 18, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2015/057416, mailed Jun. 22, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2015/057417, mailed Jun. 17, 2015.
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2015/057418, mailed Jun. 19, 2015.
Aramadhaka et al. (Apr. 18, 2013) “Connectivity maps for biosimilar drug discovery in venoms: The case of Gila Monster Venom and the anti-diabetes drug Byetta®,” Toxicon. 69:160-167.
Bhavsar et al. (Mar. 2013) “Evolution of exenatide as a diabetes therapeutic,” Curr. Diabetes Rev. 9(2):161-193.
Gao et al. (Jun. 4, 2012) “A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo,” J. Pharm. Pharmacol. 64(11):1646-1653.
Gupta (May 2013) “Glucagon-like peptide-1 analogues: An overview,” Indian J. Endocrinol. Metab. 17(3):413-421.
Hou et al. (Jan. 23, 2013) “Long-term treatment with EXf, a peptide analog of Exendin-4, improves β-cell function and survival in diabetic KKAy mice,” Peptides. 40:123-132.
Kim et al. (Nov. 9, 2012) “Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects,” Bioconjug. Chem. 23(11):2214-2220.
Lee et al. (Oct. 17, 2013) “Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system,” Acta Biomater. 10(2):812-820.
Parkes et al. (Dec. 12, 2012) “Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1,” Expert Opin. Drug Discov. 8(2):219-244.
Qian et al. (Jul. 1, 2013) “Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site,” Int. J. Pharm. 454(1):553-558.
Simonsen et al. (Jan. 11, 2013) “The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs,” Regul. Pept. 181:17-21.
Sun et al. (Nov. 6, 2013) “Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics,” J. Med. Chem. 56(22):9328-9341.
Yim et al. (Aug. 8, 2013) “Synthesis and preclinical characterization of [64Cu]NODAGA-MAL-exendin-4 with a Nε-maleoyl-L-lysyl-glycine linkage,” Nucl. Med. Biol. 40(8)1006-1012.
Yue et al. (Jan. 28, 2013) “Development of a new thiol site-specific prosthetic group and its conjugation with [Cys(40)]—exendin-4 for in vivo targeting of insulinomas,” Bioconjug. Chem. 24(7):1191-1200.
Bayram et al. (Sep. 2014) “Effects of glucagon-like peptide-1 in diabetic rat small resistance arteries,” Journal of Cardiovascular Pharmacology. 64(3):277-84.
Brom et al. (Feb. 1, 2014) “Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin,” Diabetologia. 57(5):950-959.
Cai et al. (Dec. 2014) “Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action,” Diabetologia. 57(12):2555-2565.
Charokopou et al. (Nov. 2014) “Cost-effectiveness of saxagliptin compared to GLP-1 analogues as an add-on to insulin in the treatment of type 2 diabetes mellitus from a UK health care perspective,” Value in Health. 17(7):A347. Abstract No. PDB89.
Chen et al. (Dec. 14, 2013) “Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents,” Diabetologia. 57(3):614-622.
Choi et al. (Jun. 2014) “A long-acting exendin-4 analog conjugate to the human fcfragment reveals low immunogenic potential,” Diabetes. 63(Suppl 1):A259-A260. Abstract No. 1009-P.
Clemmensen et al. (Dec. 30, 2013) “GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet,” Diabetes. 63(4):1422-1427.
De Marinis et al. (Jun. 2014) “Differential action of GLP-1 And GIP on human pancreatic islet function and viability,” Diabetes. 63(Suppl 1):A52. Abstract No. 196-OR.
De Marinis et al. (Sep. 2014) “Differential action of GLP-1 and GIP on human pancreatic islet function and viability,” Diabetologia. 57(Suppl 1):S171. Abstract No. 401.
Eriksson et al. (Feb. 10, 2014) “Detection of metastatic insulinoma by positron emission tomography with [(68)ga] exendin-4-a case report,” J. Clin. Endocrinol. Metab. 99(5):1519-1524.
Eriksson et al. (May 2014) “Effects of the glucagon-like peptide-1 analog exendin-4 on reendothelialization and intimal hyperplasia formation in an animal model of vascular injury,” Arteriosclerosis, Thrombosis, and Vascular Biology. 34(Suppl 1): Abstract No. 515.
Gong et al. (Apr. 18, 2014) “Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors,” Neuropharmacology. 84:31-45.
Gupta et al. (Sep. 25, 2014) “Mitigation of autophagy ameliorates hepatocellular damage following ischemia reperfusion injury in murine steatotic liver,” Am. J. Physiol. Gastrointest. Liver Physiol. 307(11):G1088-G1099.
Jerlhag et al. (Jun. 2014) “A glucagon like peptide-1 analogue reduces alcohol intake and prevents relapse drinking,” Alcoholism: Clinical and Experimental Research. 38(Suppl 1):85A. Abstract No. 0339.
Jin et al. (Jun. 24, 2014) “Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats,” PloS one. 9(6):e100798. pp. 1-10.
Johnson et al. (Sep. 5, 2014) “A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo,” Journal of the American Chemical Society. 136(37)12848-12851.
Kwon et al. (Sep. 2014) “Pharmacological evaluation of once-weekly potentials by combination of long-acting insulin with long-acting exendin4 in an animal model,” Diabetologia. 57(Suppl 1):5398-5399. Abstract No. 972.
Li et al. (Apr. 2014) “Vascular protective effect of exendin-4 in experimental models of oxidative stress,” Cytotherapy. 16(4 Suppl):S37-S38. Abstract No. 115.
Li et al. (Nov. 5, 2014) “Exendin-4 promotes endothelial barrier enhancement via PKA-and Epac1-dependent Rac1 activation,” American Journal of Physiology. 308(2):C164-C175.
Lim et al. (Nov. 18, 2014) “Evaluation of PEGylated Exendin-4 Released from Poly (Lactic-co-Glycolic Acid) Microspheres for Antidiabetic Therapy,” Journal of Pharmaceutical Sciences. 104(11:72-80.
Lovshin et al. (Oct. 2014) “Blood pressure-lowering effects of incretin-based diabetes therapies,” Canadian Journal of Diabetes. 38(5):364-71.
Lynch et al. (Jun. 24, 2014) “A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation,” Diabetologia. 57(9):1927-1936.
Maas et al. (Oct. 2014) “Impact of the mTOR inhibitor Everolimus on peptide receptor radionuclide therapy in a transgenic neuroendocrine tumor mouse model,” European Journal of Nuclear Medicine and Molecular Imaging. 41 (Suppl 2):S529. Abstract No. P593.
Masjkur et al. (Nov. 4, 2014) “Hes3 is Expressed in the Adult Pancreatic Islet and Regulates Gene Expression, Cell Growth, and Insulin Release,” The Journal of Biological Chemistry. 289(51):35503-35516.
Mondragon et al. (Aug. 13, 2014) “Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia,” PloS one. 9(8):e104873. pp. 1-9.
Nagai et al. (Sep. 2014) “Effects of sitagliptin on body fat and intrahepatic lipid content in Japanese overweight patients with type 2 diabetes,” Diabetologia. 57(Suppl 1):S356. Abstract No. 876.
Patel et al. (Sep. 29, 2014) “Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice,” Canadian Journal of Physiology and Pharmacology. 92(12):975-983.
Pathak et al. (Nov. 6, 2014) “Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice”; Molecular and Cellular Endocrinology. 401:120-129.
Pi et al. (2014) “ [Clinical research progresses on glucagon-like peptide-1 analogs in treatment of diabetes mellitus],” [Jianyan Yixue Yu Linchuang]. 11(6):830-832.—with English machine translation.
Qian et al. (Jun. 19, 2014) “Analysis of the interferences in quantitation of a site-specifically PEGylated exendin-4 analog by the Bradford method,” Analytical Biochemistry. 465C:50-52.
Roed et al. (Nov. 22, 2013) “Real-time trafficking and signaling of the glucagon-like peptide-1 receptor,” Mol. Cell Endocrinol. 382(2):938-949.
Russell et al. (Jun. 2014) “The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and mproves insulin sensitivity in DIO mice,” Diabetes. 63(Suppl 1):A98. Abstract No. 374-OR.
Schattauer GMBH (Jun. 12, 2014) Meeting Abstracts of the Swiss Society of Radiology and the Swiss Society of Nuclear Medicine 2014. Nuklearmedizin. 53(2):A111-A126.
Tashiro et al. (Jan. 10, 2014) “A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis,” Peptides. 54:19-26.
Tweedie et al. (May 2014) “Exendin-4, a candidate treatment for the clinical management of traumatic brain injury,” Brain Injury. 28(5-6):549-550. Abstract No. 0101.
Vioix et al. (Nov. 2014) “Cost-minimisation analysis of dapagliflozin compared to lixisenatide as an add-on to insulin in the treatment of type 2 diabetes mellitus from a UK health care perspective,” Value in Health. 17(7):A348. Abstract No. PDB95.
Wang et al. (Jun. 2014) “Microfluidic multiplexer perifusion device for studying islet immunotoxicity,” Diabetes. 63 (Suppl 1):A555. Abstract No. 2181-P.
Wu et al. (May 24, 2014) “(64)Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression,” Theranostics. 4(8):770-777.
Xu et al. (Feb. 11, 2014) “Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway,” Cell. Physiol. Biochem. 33(2):423-432.
Xu et al. (Sep. 2014) “Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4,” Journal of Cancer Research and Clinical Oncology. 140(9): 1479-1488.
Yang et al. (2014) “Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents,” European Journal of Medicinal Chemistry. 73:105-111.
Yang et al. (Jun. 2014) “Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity,” J. Physiol. Pharmacol. 65(3):349-357.
Yosida et al. (May 13, 2014) “Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion,” Diabetes. 63(10):3394-3403.
Zhang et al. (Aug. 2014) “GLP-1 ameliorates the proliferation activity of INS-1 cells inhibited by intermittent high glucose concentrations through the regulation of cyclins,” Molecular Medicine Reports. 10(2):683-688.
Stoessl et al. (2008) “Potential therapeutic targets for Parkinson's disease,” Expert Opinion on Therapeutic Targets. 12(4):425-436.
European Search Report corresponding to European Patent Application No. 13305222, dated Jul. 15, 2013.
Related Publications (1)
Number Date Country
20150164997 A1 Jun 2015 US